WO2022217821A1 - 炔苯基苯酰胺类化合物及其应用 - Google Patents

炔苯基苯酰胺类化合物及其应用 Download PDF

Info

Publication number
WO2022217821A1
WO2022217821A1 PCT/CN2021/117495 CN2021117495W WO2022217821A1 WO 2022217821 A1 WO2022217821 A1 WO 2022217821A1 CN 2021117495 W CN2021117495 W CN 2021117495W WO 2022217821 A1 WO2022217821 A1 WO 2022217821A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
alkyl
unsubstituted
independently selected
pharmaceutically acceptable
Prior art date
Application number
PCT/CN2021/117495
Other languages
English (en)
French (fr)
Inventor
陆小云
张章
丁克
项双
王杰
涂正超
张志民
唐霞
王祖勤
何询
金锋
张水华
李振伟
Original Assignee
深圳市新樾生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市新樾生物科技有限公司 filed Critical 深圳市新樾生物科技有限公司
Priority to KR1020237038624A priority Critical patent/KR20230170938A/ko
Priority to JP2023564002A priority patent/JP2024514015A/ja
Priority to AU2021440841A priority patent/AU2021440841A1/en
Priority to BR112023021215A priority patent/BR112023021215A2/pt
Priority to EP21936693.7A priority patent/EP4324833A1/en
Priority to US17/948,236 priority patent/US11834454B2/en
Publication of WO2022217821A1 publication Critical patent/WO2022217821A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the technical field of chemical medicine, in particular to an alkynylphenylbenzamide compound and an application thereof.
  • TRK tropomyosin receptor kinase
  • RTK receptor tyrosine kinase family
  • TRKA receptor tyrosine kinase family
  • TRKB receptor tyrosine kinase family
  • TRKC receptor tyrosine kinase
  • NTRK1, NTRK2, NTRK3 coding TRK is a kind of transmembrane protein, which is composed of extracellular ligand binding domain, transmembrane domain (TM) and intracellular domain. TRK mainly acts by binding neurotrophic factors (NTs).
  • Neurotrophic factors are a class of protein molecules that are produced by nerve-innervated tissues (such as muscles) and astrocytes and are essential for neuronal growth and survival.
  • NGF nerve growth factor
  • BDNF brain-derived neurotrophic factor
  • NT-3 neurotrophic factor 3
  • NT-4 neurotrophic factor 4
  • NGF binds to TRKA
  • BDNF and NT-4 bind to TRKB
  • NT-3 can bind to three TRK proteins, but its binding ability to TRKC is stronger.
  • TRK When activated by signal induction, TRK activates downstream signaling pathways through self-dimerization and phosphorylation to achieve various cellular physiological functions.
  • TRK The downstream signaling pathways of TRK include MAPK, PI3K/AKT, and PLC ⁇ /PKC pathways. These signaling pathways regulate physiological processes such as cell proliferation, differentiation, migration, and apoptosis, as well as the elasticity of neural synapses and the growth and repair of neural dendrites. , the prevention and repair of neuronal degradation, and the maintenance of sensory neurons and other physiological activities related to neurons.
  • TRK overexpression, gene fusion and single nucleotide changes are closely related to the occurrence and development of various types of tumors, such as non-small cell lung cancer, breast cancer, colon cancer, prostate cancer, thyroid cancer, malignant melanoma, Neuroblastoma and breast-like secretory carcinoma, etc.
  • tumors such as non-small cell lung cancer, breast cancer, colon cancer, prostate cancer, thyroid cancer, malignant melanoma, Neuroblastoma and breast-like secretory carcinoma, etc.
  • the earliest NTRK fusion gene discovered in medical research was the TPM3-NTRK1 fusion gene found in colon cancer samples.
  • TPM3-NTRK1 fusion gene found in colon cancer samples.
  • TRK fusion protein expressed by the NTRK fusion gene can continuously activate downstream signaling pathways independent of ligand binding, thereby inducing abnormal cell proliferation and promoting the occurrence and development of tumors. Therefore, TRK is regarded as an effective anticancer therapeutic target.
  • Larotrectinib a selective inhibitor of TRK developed by LOXO in the United States, was approved by the FDA in 2018. Entrectinib, a TRK inhibitor developed by Roche Pharmaceuticals, was launched in Japan in June 2019. Belizatinib developed by TESARO Clinical studies are underway, and multi-target inhibitors such as Cabozanitinib, Sitravatinib, and Altiratinib also have good TRK inhibitory activity.
  • NTRK NTRK gene caused by continuous use of TRK inhibitors
  • Clinical studies have successively discovered G595R, G667C, F589L, G667S of NTRK1 and G623R, G696A of NTRK3 mutations. There are no inhibitors against these mutations on the market.
  • the second-generation TRK inhibitors LOXO-195, TPX-0005 and ONO-5390556 is under clinical research.
  • the present invention provides an alkynyl phenyl benzamide compound or a pharmaceutically acceptable salt or a stereoisomer thereof, which can be used as a protein kinase inhibitor, can effectively inhibit the activity of TRK protein kinase and It can inhibit the proliferation, migration and invasion of various tumor cells, especially it has good pharmacokinetic properties and anti-drug resistance.
  • alkynyl phenylbenzamide compound having the structure of formula (I) or its pharmaceutically acceptable salt or its stereoisomer or its prodrug molecule;
  • R 1 is optionally selected from: C 1 -C 20 alkyl
  • R 2 is optionally selected from: H, halogen, C 1 -C 20 alkyl, C 1 -C 20 alkoxy or halogen-substituted C 1 -C 20 alkyl;
  • R 3 is optionally selected from: H, fluorine-substituted C 1 -C 4 alkyl, substituted or unsubstituted 5-6 membered heterocyclic group containing 1-3 N ring atoms;
  • R 4 is optionally selected from: H, halogen, nitro, substituted or unsubstituted C 1 -C 20 alkyl, substituted or unsubstituted C 1 -C 20 alkoxy, substituted or unsubstituted containing 1-3 5-10-membered heterocyclic group of N ring atoms, substituted or unsubstituted 5-10-membered heteroaryl group containing 1-3 N ring atoms;
  • R 5 is -NR 6 R 7 ;
  • R 6 and R 7 are independently selected from: -(CH 2 ) m NR 8 R 9 , -(CH 2 ) n CR 10 R 11 R 12 , -(CH 2 ) p OR 12 , or R 6 , R 7 together with the nitrogen atom to which they are attached form a substituted or unsubstituted heteroatom-containing monocyclic, fused, spiro or bridged ring;
  • R 8 and R 9 are independently selected from: H, C 1 -C 20 alkyl; or R 8 and R 9 together with the nitrogen atom to which they are attached form a substituted or unsubstituted heteroatom containing 1-3 atoms The monocyclic, fused, spiro or bridged ring;
  • R 10 and R 11 together with the carbon atoms to which they are attached form a substituted or unsubstituted monocyclic, condensed, spiro or bridged ring containing 1-3 heteroatoms;
  • R 12 is selected from: H, C 1 -C 20 alkyl
  • n, and p are each independently selected from: an integer of 0-10.
  • R 17 , R 18 together with the nitrogen atom to which they are attached form morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl substituted or unsubstituted by 1-5 R 19 ;
  • Each R 19 is independently selected from C 1 -C 5 alkyl.
  • R 4 is optionally selected from: H, halogen, nitro, C 1 -C 8 alkyl, halogen substituted C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halogen substituted C 1 -C 8 alkoxy, -(CH 2 ) x NR 17 R 18 , 5-6 membered heterocyclic group containing 1-3 N ring atoms substituted or unsubstituted by 1-5 R 19 , a 5-6-membered heteroaryl group containing 1-3 N ring atoms substituted or unsubstituted by 1-5 R 19 ; x is an integer of 1-5.
  • R 4 is optionally selected from: H, halogen, nitro, C 1 -C 4 alkyl, halogen substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halogen substituted C 1 -C 4 alkoxy, -(CH 2 ) x NR 17 R 18 , imidazolyl substituted or unsubstituted by 1-3 R 19 ; x is 1, 2 or 3;
  • R 17 , R 18 together with the nitrogen atom to which they are attached form a piperazinyl substituted or unsubstituted by 1-3 R 19 ;
  • Each R 19 is independently selected from: C 1 -C 5 alkyl.
  • R4 is optionally selected from: H, halogen, nitro, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoroethyl ,
  • Each R 19 is independently selected from: methyl, ethyl, propyl.
  • R 6 and R 7 are independently selected from: -(CH 2 ) m NR 8 R 9 , -(CH 2 ) n CR 10 R 11 R 12 , -(CH 2 ) p OR 12 , or R 6 , R 7 and the nitrogen atom to which they are attached together form a 3-15-membered monocyclic, fused ring, spiro ring or 1-3 heteroatoms substituted or unsubstituted by 1-5 R 13 Bridged ring, heteroatom is selected from: O, N, S;
  • R 8 , R 9 are independently selected from: H, C 1 -C 5 alkyl; or R 8 , R 9 together with the nitrogen atom to which they are attached form a substituted or unsubstituted containing 1-5 R 13 3-10-membered monocyclic, condensed, spiro or bridged rings with 1-3 heteroatoms, the heteroatoms are selected from: O, N;
  • R 10 , R 11 and the carbon atoms to which they are attached together form a 3-10-membered monocyclic, fused, spiro or bridged ring containing 1-3 heteroatoms substituted or unsubstituted by 1-5 R 13 , the heteroatom is selected from: O, N;
  • R 12 is selected from: H, C 1 -C 5 alkyl
  • Each R 13 is independently selected from: H, C 1 -C 5 alkyl, C 1 -C 5 alkanoyl, hydroxy, hydroxy substituted C 1 -C 5 alkyl, amino substituted C 1 -C 5 alkyl , C 1 -C 5 alkoxy substituted by amino, C 1 -C 3 alkyl substituted by C 3 -C 7 cycloalkyl, -NR 15 R 16 , substituted by 1-5 R 14 or unsubstituted A 3-10-membered monocyclic, condensed, spiro or bridged ring containing 1-3 heteroatoms, the heteroatoms are selected from: O, N;
  • R 14 , R 15 and R 16 are each independently selected from: H, C 1 -C 5 alkyl;
  • n, p are each independently selected from: an integer of 0-5.
  • R 6 , R 7 are independently selected from: -(CH 2 ) m NR 8 R 9 , -(CH 2 ) p OR 12 , or R 6 , R 7 and the nitrogen to which they are attached Atoms together form morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl substituted or unsubstituted by 1-3 R 13 ;
  • R 8 and R 9 are independently selected from: H, C 1 -C 5 alkyl, or R 8 and R 9 together with the nitrogen atoms to which they are attached form a substituted or unsubstituted 1-5 R 13 olinyl, pyrrolidinyl, piperidinyl or piperazinyl;
  • R 12 is selected from: H, C 1 -C 5 alkyl
  • Each R 13 is independently selected from: H, C 1 -C 5 alkyl, C 1 -C 5 alkanoyl, hydroxy, -NR 15 R 16 , oxa substituted or unsubstituted with 1-2 R 14 Cyclobutyl, morpholinyl substituted or unsubstituted by 1-4 R 14 ;
  • R 14 , R 15 and R 16 are each independently selected from: H, C 1 -C 3 alkyl;
  • n and p are independently selected from: 1, 2, 3, 4 or 5.
  • R 5 is selected from any of the following groups:
  • R 4 is halogen;
  • R 5 is -NR 6 R 7 ;
  • R 6 , R 7 are independently selected from: -(CH 2 ) m NR 8 R 9 , -(CH 2 ) p OR 12 , or R 6 and R 7 together with the nitrogen atoms to which they are attached form a compound consisting of 1-3 R 13 substituted or unsubstituted morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl;
  • R 8 , R 9 are independently selected from: H, C 1 -C 3 alkyl, or R 8 , R 9 together with the nitrogen atom to which they are attached form a substituted or unsubstituted 1-2 R 13 olinyl, pyrrolidinyl, piperidinyl or piperazinyl;
  • R 12 is selected from: H, C 1 -C 3 alkyl
  • Each R 13 is independently selected from: H, C 1 -C 3 alkyl, acetyl, hydroxyl, -NR 15 R 16 , oxetanyl, morpholinyl;
  • R 15 and R 16 are independently selected from: H, C 1 -C 3 alkyl
  • n and p are independently selected from: 2, 3 or 4.
  • R 4 is Cl
  • R 5 is selected from:
  • R 4 is selected from: H, halogen, methyl, methoxy, trifluoromethyl, nitro, R5 is
  • R 4 is selected from: H
  • R 5 is selected from:
  • R 1 is optionally selected from: C 1 -C 10 alkyl.
  • R 1 is optionally selected from: C 1 -C 4 alkyl.
  • R 1 is optionally selected from: methyl, ethyl, isopropyl, tert-butyl.
  • R 2 is optionally selected from: H, halogen, C 1 -C 10 alkyl, halogen substituted C 1 -C 10 alkyl.
  • R 2 is optionally selected from: H, halogen, C 1 -C 4 alkyl, halogen substituted C 1 -C 4 alkyl, C 1 -C 4 alkoxy.
  • R is optionally selected from: hydrogen , fluoro, methyl, ethyl, isopropyl, tert-butyl, difluoromethyl, difluoroethyl, trifluoromethyl, or trifluoroethyl .
  • R 3 is selected from the group consisting of: H, difluoromethyl, difluoroethyl, trifluoromethyl, or trifluoroethyl.
  • the alkynyl phenyl benzamide compound has the structure shown in formula (II):
  • Another object of the present invention is to provide an application of the above-mentioned alkynylphenylbenzamide compound or its pharmaceutically acceptable salt or its stereoisomer or its prodrug molecule in preparing a TRK inhibitor.
  • Another object of the present invention is to provide a kind of above-mentioned alkynyl phenylbenzamide compound or its pharmaceutically acceptable salt or its stereoisomer or its prodrug molecule in the preparation of prevention and/or treatment by TRK tyrosine Drug application in kinase-mediated diseases.
  • the disease mediated by TRK tyrosine kinase is a tumor, preferably non-small cell lung cancer, breast cancer, colon cancer, prostate cancer, thyroid cancer, malignant melanoma, neuroblastoma or Breast-like secretory carcinoma.
  • Another object of the present invention is to provide a pharmaceutical composition for preventing and/or treating tumors, comprising an active ingredient and a pharmaceutically acceptable excipient, the active ingredient comprising the above-mentioned alkynyl phenyl benzamide compound or its pharmacy an acceptable salt thereof or a stereoisomer thereof or a prodrug molecule thereof.
  • the alkynyl phenylbenzamide compounds provided by the invention have strong inhibitory activity on TRKs kinase, and have strong inhibitory activity on the proliferation of wild-type and drug-resistant cells of Ba/F3-TRKs stable strain.
  • Figure 1 shows the in vivo antitumor activity of compound XS3-55.
  • Figure 2 shows the effect of compound XS3-55 on the body weight of mice.
  • the "plurality” mentioned in the present invention means two or more.
  • "And/or" which describes the association relationship of the associated objects means that there can be three kinds of relationships, for example, A and/or B, which can mean that A exists alone, A and B exist at the same time, and B exists alone.
  • the character "/" generally indicates that the associated objects are an "or" relationship.
  • any variable eg, R 10 , R 11 , etc.
  • the definition of each occurrence is independent of the definition of each other occurrence.
  • combinations of substituents and variables are permissible so long as such combinations stabilize the compound.
  • a line drawn into a ring system from a substituent indicates that the indicated bond may be attached to any substitutable ring atom. If the ring system is polycyclic, it means that such bonds are only attached to any suitable carbon atoms adjacent to the ring.
  • alkyl as used herein is meant to include branched and straight chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • C 1 -C 20 in “C 1 -C 20 alkyl” includes groups having 1, 2, 3, 4, 5, ... or 20 carbon atoms in a straight or branched chain arrangement group.
  • cycloalkyl refers to a monocyclic saturated aliphatic hydrocarbon group having the specified number of carbon atoms.
  • C 3 -C 7 cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • alkoxy refers to a group in which an alkyl group is directly attached to oxygen, that is, a group having an -O-alkyl structure, such as -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 CH 3 , -O - CH2CH( CH3 ) 2 , -OCH2CH2CH2CH3, -O - CH ( CH3 ) 2 , etc.
  • heterocyclyl refers to a non-aromatic heterocyclic group containing one or more heteroatoms selected from O, N and S, eg: piperidinyl, tetrahydropyrrolyl (pyrrolidinyl) , morpholino, piperazinyl, etc. Attachment of heterocyclic substituents can be through a carbon atom or through a heteroatom.
  • heteroaryl refers to an aromatic ring containing one or more heteroatoms selected from O, N or S.
  • Heteroaryl groups within the scope of the present invention include, but are not limited to: quinolyl, pyrazolyl, Pyrrolyl, thienyl, furyl, pyridyl, pyrimidinyl, pyrazinyl, triazolyl, imidazolyl, oxazolyl, isoxazolyl, pyridazinyl, benzofuranyl, benzothienyl, Benzoxazole, indolyl, etc.; "heteroaryl” is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl.
  • the attachment of the heteroaryl group can be through a carbon atom or through a heteroatom.
  • substituted refers to the replacement of a hydrogen group in a particular structure with a group of the designated substituent.
  • halogen as used herein is meant to include chlorine, fluorine, bromine and iodine.
  • the present invention includes compounds of formula (I) or formula (II) in free form, as well as pharmaceutically acceptable salts thereof, stereoisomers thereof, and prodrug molecules thereof.
  • free form refers to a compound in non-salt form. Included pharmaceutically acceptable salts include not only exemplary salts of the particular compounds described herein, but also typical pharmaceutically acceptable salts of all compounds of formula (I) or formula (II) in free form. The free forms of specific salts of the compounds can be isolated using techniques known in the art.
  • the free form can be regenerated by treating the salt with a suitable dilute aqueous base, such as dilute aqueous NaOH, dilute aqueous potassium carbonate, dilute aqueous ammonia, and dilute aqueous sodium bicarbonate.
  • a suitable dilute aqueous base such as dilute aqueous NaOH, dilute aqueous potassium carbonate, dilute aqueous ammonia, and dilute aqueous sodium bicarbonate.
  • the free forms differ somewhat from their respective salt forms in certain physical properties such as solubility in polar solvents, but for the purposes of the invention such acid and base salts are otherwise pharmaceutically equivalent to their respective free forms.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from compounds of the present invention containing a basic or acidic moiety by conventional chemical methods.
  • salts of basic compounds are prepared by ion exchange chromatography or by reacting the free base and a stoichiometric amount or excess of an inorganic or organic acid in the desired salt form in a suitable solvent or combination of solvents.
  • salts of acidic compounds are formed by reaction with a suitable inorganic or organic base.
  • pharmaceutically acceptable salts of the compounds of the present invention include conventional non-toxic salts of the compounds of the present invention formed by reacting a basic compound of the present invention with an inorganic or organic acid.
  • conventional non-toxic salts include those prepared from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like, as well as those derived from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid , stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, p-aminobenzenesulfonic acid, 2 - Salts prepared from acetoxymonobenzoic acid, fumaric acid, benzenesulfonic acid, toluen
  • salts refer to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, iron, ferrous, lithium, magnesium, manganese, manganous, potassium, sodium, zinc, and the like. Ammonium, calcium, magnesium, potassium and sodium salts are particularly preferred.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases including salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins such as Amino acid, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, aminoethanol, ethanolamine, ethyl Diamine, N-Ethylmorpholine, N-Ethylpiperidine, Glucosamine, Glucosamine, Histidine, Hydroxocobalamin, Isopropylamine, Lysine, Methylglucamine, Morpholine, Piperazine , Piperidine, quack, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.
  • Example 1 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-2-methyl-N-(3-((4-methylpiperazin-1-yl)methan yl)-5-(trifluoromethyl)phenyl)benzamide (named XS116)
  • the crude product in the previous step was dissolved in methanol, about 20 mL of a 1 mol/L tetrabutylammonium fluoride solution in tetrahydrofuran was added, and the mixture was stirred at room temperature for 2 hours.
  • the reaction system was spin-dried and subjected to column chromatography to obtain 4 g of a yellow-brown oil (the total yield of two steps was 63%).
  • Step 4 3-Ethynyl-2-methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide ( Preparation of compound 6)
  • Step 5 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-2-methyl-N-(3-((4-methylpiperazin-1-yl)methyl )-5-(trifluoromethyl)phenyl)benzamide (XS116) preparation
  • Step 1 Preparation of methyl 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-2-methylbenzoate (compound 3)
  • Step 2 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-2-methylbenzoic acid (compound 4)
  • Step 3 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-2-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (XS2- 106)
  • Step 1 Prepared from 3-ethynyl-2-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (compound 3)
  • reaction system was spin-dried, water was added, extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, the solvent was spin-dried, and 150 mg of yellow oil was obtained by column chromatography (yield 80%).
  • Step 2 Preparation of 4-(3-iodoimidazo[1,2-b]pyridazin-6-yl)morpholine (Compound 5)
  • Step 3 2-Methyl-3-((6-morpholinoimidazo[1,2-b]pyridazin-3-yl)ethynyl)-N-(3-(trifluoromethyl)phenyl ) preparation of benzamide (XS3-23)
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • Example 13 2-Methyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-3-((6- Preparation of linoimidazo[1,2-b]pyridazin-3-yl)ethynyl)benzamide (named XS3-68)
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • Example 17 3-((6-(4-(Dimethylamino)piperidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)ethynyl)-2-methyl - Preparation of N-(3-(trifluoromethyl)phenyl)benzamide (designated as XS3-57)
  • the synthetic method is as in Example 6.
  • Example 18 N-(3-Chloro-5-(trifluoromethyl)phenyl)-3-((6-(4-(dimethylamino)piperidin-1-yl)imidazo[1, Preparation of 2-b]pyridazin-3-yl)ethynyl)-2-methylbenzamide (named XS3-56)
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • Example 22 N-(3-Chloro-5-(trifluoromethyl)phenyl)-3-((6-(4-hydroxypiperidin-1-yl)imidazo[1,2-b]pyridin Preparation of oxazin-3-yl)ethynyl)-2-methylbenzamide (named XS3-55)
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • Example 25 3-((6-(4-Hydroxypiperidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)ethynyl)-2-methyl-N-(3 Preparation of -(((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide (designated as XS3-81)
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • Example 27 N-(3-Chloro-5-(trifluoromethyl)phenyl)-2-methyl-3-((6-(4-(oxetan-3-yl)piperazine) Preparation of -1-yl)imidazo[1,2-b]pyridazin-3-yl)ethynyl)benzamide (designated as XS3-138)
  • the synthetic method is as in Example 6.
  • Example 28 N-(3-Chloro-5-(trifluoromethyl)phenyl)-3-((6-((2-(dimethylamino)ethyl)(methyl)amino)imidazo[ Preparation of 1,2-b]pyridazin-3-yl)ethynyl)-2-methylbenzamide (named XS3-134)
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • the synthetic method is as in Example 6.
  • Step 1 Preparation of 4-methyl-1-(3-nitro-5-(trifluoromethyl)phenyl)-1H-imidazole (compound 3)
  • Step 2 Preparation of 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline (compound 4)
  • reaction system was spin-dried, water was added, extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, the solvent was spin-dried, and 220 mg of yellow oil was obtained by column chromatography (yield 51%).
  • Step 4 2-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((6-morpholinimidazole Preparation of [1,2-b]pyrido-3-ylethynyl)benzamide (designated as XS3-91)
  • Example 36 3-((6-(4-Hydroxypiperidin-1-yl)imidazo[1,2-b]pyridazin-3-yl)ethynyl)-2-methyl-N-(3 Preparation of -(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide (designated as XS3-87)
  • the synthetic method is as in Example 35.
  • Z'-LYTE TM technology detection by fluorescence, enzyme-coupled form, based on the difference in sensitivity of phosphorylated and non-phosphorylated polypeptides to proteolytic cleavage), using fluorescence resonance energy transfer (FRET)
  • FRET fluorescence resonance energy transfer
  • Z′-LYTE TM FRET peptide substrate was used to detect the inhibitory activity of compounds on TRKs (TRK1, TRK2, TRK3) kinases (American Life Technologies, PV3144, PV3616, PV3617) by secondary reaction.
  • Enzymatic reaction In a 384-well plate, add 5 ⁇ L of enzyme-substrate system [50 mM 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES) pH 7.5, 0.01% BRIJ-35, 10 mM magnesium chloride (MgCl 2 ), 1 mM ethylene glycol Bis(2-aminoethyl ether)tetraacetic acid (EGTA), 2 ⁇ M Tyr 01 peptide substrate, transferred into 5nL compound (concentration gradient) using echo520 ultra-micro liquid pipetting system, after shaking at room temperature for 10-20min, using echo520 ultra-micro volume The liquid pipetting system was transferred into 200nL, 12.5nL, and 25nL ATP (final concentrations were 400uM, 25uM, 50uM, respectively), shaken and mixed, centrifuged, and reacted at 30°C for 1.5h in the dark.
  • enzyme-substrate system [50 mM 4-hydroxyethylpiperazine e
  • Detection reaction Add 2.5 ⁇ L of development solution (1:128 dilution) to each well and incubate at 37°C for 1 h in the dark, and then add 5 ⁇ L of stop solution (Stop Reagent).
  • Perkin Elmer EnVision Multimode Plate Reader detects the fluorescence signal (excitation wavelength is 400nm, emission wavelength is 460nm, 535nm).
  • Phosphorylation ratio 1– ⁇ (Emission ratio ⁇ F100%–C100%)/[C 0%–C 100%+Emission ratio ⁇ (F100%–F0%)] ⁇ 100;
  • Inhibition rate 100 ⁇ (1-compound phosphorylation ratio/negative control phosphorylation ratio).
  • the IC 50 value was calculated using the medical drawing software (GraphPad Prism5.0).
  • Example 38 Cell proliferation inhibitory activity based on Ba/F3-TRKs stable strain
  • the BaF3 cells (mouse pre-B cells) used in this experiment were purchased from the Japanese Cell Bank. The experimental identification of activity, protein expression and gene sequencing was completely correct.
  • the brief steps for stable strain construction are as follows: construct pCDNA3.1(+) plasmid vector carrying genes such as CD74-NTRK1, ETV6-NTRK2, ETV6-NTRK3; use Cell Line
  • the plasmid was electroporated into Ba/F3 cells with Kit V kit; 48 hours after electroporation, geneticin (G418) with a final concentration of 1000 ⁇ g/ml was added for two weeks and the interleukin 3 (IL3) was removed to continue the selection to obtain polyclonal stability.
  • G418 geneticin
  • IL3 interleukin 3
  • Cell proliferation inhibitory activity study cells in logarithmic growth phase were seeded into 96-well plates at 8000-12000 cells/well, different concentrations of inhibitors (0-10 ⁇ M) were added the next day, and the culture was continued for 72 hours; then 10 ⁇ L per well was added Cell Counting Kit-8 cell counting reagent (CCK-8 reagent), continue to incubate for 1-3 hours; then measure its absorbance at 450nm and 650nm with a super microplate reader. The median inhibitory concentration ( IC50 ) was calculated using medical graphing software (GraphPad Prism 8.0.0).
  • Example 39 Study on the inhibitory activity of drug-resistant cell proliferation based on Ba/F3-TRKs stable strain
  • BaF3 cells (mouse pre-B cells) used in this experiment were purchased from Japan Cell Bank, BaF3-CD74-NTRK1-G667C, BaF3-CD74-NTRK1-F589L, BaF3-CD74-NTRK1-G595R, BaF3-CD74-NTRK1-G667A , BaF3-CD74-NTRK1-V573M, BaF3-ETV6-NTRK2-G639R, BaF3-ETV6-NTRK2-G709C, BaF3-ETV6-NTRK2-V617M, BaF3-ETV6-NTRK2-F633L, BaF3-ETV6-NTRK3-G696C, BaF3 -ETV6-NTRK3-G696A, BaF3-ETV6-NTRK3-G623R, BaF3-ETV6-NTRK3-G623E, BaF3
  • Cell proliferation inhibitory activity study cells in logarithmic growth phase were seeded into 96-well plates at 8000-12000 cells/well, different concentrations of inhibitors (0-10 ⁇ M) were added the next day, and the culture was continued for 72 hours; then 10 ⁇ L per well was added Cell Counting Kit-8 Cell Counting Reagent (CCK-8) reagent, continue to incubate for 1-3 hours; then measure its absorbance at 450nm and 650nm with a super microplate reader. The median inhibitory concentration ( IC50 ) was calculated using medical graphing software (GraphPad Prism 8.0.0).
  • alkynyl phenylbenzamide compounds of the present invention have strong inhibitory activity on the proliferation of drug-resistant cells of the Ba/F3-TRKs stable strain.
  • Example 40 IC50 test of compound XS3-55 kinase selectivity
  • kinase activity detection Z'-LYTE TM technology (detection by fluorescence, enzyme-coupled form, based on the difference in sensitivity of phosphorylated and non-phosphorylated polypeptides to proteolytic cleavage), using fluorescence resonance energy transfer (FRET) Principle, using Z'-LYTE TM FRET peptide substrate, secondary reaction detection compound XS3-55 and control molecule XS4-128 and Ponatinib (Ponatinib) on Bcr-Abl, SRC, RET,, PDGFRA, PDGFRB, Inhibitory activity of VEGFR2 and Kit kinases.
  • FRET fluorescence resonance energy transfer
  • the crude product in the previous step was dissolved in methanol, about 2 mL of a 1 mol/L tetrabutylammonium fluoride solution in tetrahydrofuran was added, and the mixture was stirred at room temperature for 2 hours.
  • the reaction system was spin-dried, and 470 mg of yellow-brown oil was obtained by column chromatography (total yield of two steps: 75%).
  • Step 4 Preparation of N-(3-chloro-5-(trifluoromethyl)phenyl)-3-ethynyl-4-methylbenzamide (compound 6)
  • Step 5 N-(3-Chloro-5-(trifluoromethyl)phenyl)-3-((6-(4-hydroxypiperidin-1-yl)imidazo[1,2-B]pyridazine- Preparation of 3-yl)ethynyl)-4-methylbenzamide (XS4-128)
  • Enzymatic reaction In a 384-well plate, add 5 ⁇ L of enzyme-substrate system (50 mM 4-hydroxyethylpiperazine ethanesulfonic acid (HEPES) pH7.5, 0.01% BRIJ-35, 10 mM magnesium chloride (MgCl 2 ), 1 mM ethyl acetate Diol bis (2-aminoethyl ether) tetraacetic acid (EGTA), 2 ⁇ M Tyr 01 peptide substrate), use echo520 ultra-micro liquid pipetting system to transfer 5nL compound (concentration gradient), after shaking at room temperature for 10-20min, use The echo520 ultra-micro liquid pipetting system was transferred into 200nL, 12.5nL, 25nL ATP (final concentrations were 400uM, 25uM, 50uM, respectively), shaken and mixed, centrifuged, and reacted at 30°C for 1.5h in the dark.
  • enzyme-substrate system 50 mM 4-hydroxyethylpiperaz
  • Detection reaction Add 2.5 ⁇ L of Development Solution (1:128 dilution) to each well and incubate at 37°C for 1 h in the dark, and then add 5 ⁇ L of Stop Reagent.
  • Perkin Elmer EnVision Multimode Plate Reader detects the fluorescence signal (excitation wavelength is 400nm, emission wavelength is 460nm, 535nm).
  • Phosphorylation ratio 1– ⁇ (Emission ratio ⁇ F100%–C100%)/[C 0%–C 100%+Emission ratio ⁇ (F100%–F0%)] ⁇ 100;
  • Inhibition rate 100 ⁇ (1-compound phosphorylation ratio/negative control phosphorylation ratio).
  • the IC 50 value was calculated using the medical drawing software (GraphPad Prism5.0).
  • the representative compound XS3-55 of the alkynyl phenyl benzamides of the present invention has weak inhibitory activity on a variety of representative tyrosine kinases other than TRKA, TRKB and TRKC, and it has good inhibitory activity.
  • the kinase selectivity is far better than that of the compounds XS4-128 and Ponatinib. Therefore, the alkynyl phenylbenzamide compounds of the present invention have good selectivity and low toxic and side effects.
  • Compound XS3-55 has strong inhibitory activity on TRKs kinase, and has strong inhibitory activity on wild-type and drug-resistant cell proliferation of Ba/F3-TRKs stable strain. And compound XS3-55 has good oral absorption properties. Under the oral dose of 10mg/kg in rats, the half-life of compound XS3-55 is 15.19 hours, the highest blood concentration is as high as 44066.54ng/mL, and the area under the curve is as high as 878346.33h*ng/mL, the pharmacokinetic properties were significantly higher than that of the control compound 9o.
  • Example 42 In vivo tumor activity of compound XS3-55
  • the in vivo antitumor efficacy of compound XS3-55 was evaluated in a Ba/F3-CD74-TRKA G667C allograft mouse model by oral administration.
  • the cultured BaF3-CD74-TRKA G667C cells were collected, centrifuged, washed twice with normal saline, adjusted to a density of 1 ⁇ 10 7 cells/mL, placed on ice, and injected subcutaneously into the right axilla of CB17-SCID female mice as soon as possible (purchased). From Beijing Weitonglihua, 6-8 weeks old), each was injected with 200 ⁇ L. After 9 days of modeling, when the tumor volume grew to about 200mm, the mice were randomly divided into groups and started to be administered.
  • mice There were 8 mice in the control group and four dose groups of compound XS3-55 (50, 25, 12.5, 6.25 mg/kg) in each group. 6 mice.
  • the administration method is as follows: according to the dosage, weigh an appropriate amount of compound XS3-55 powder and dissolve it in a mixed solvent of 2% dimethyl sulfoxide (DMSO) + 20% hydrogenated castor oil + 8% absolute ethanol + 70% normal saline , a light yellow to yellow transparent liquid was obtained, which was administered orally, once a day; the control group was administered orally with the same volume of mixed solvent. Body weight and tumor volume were recorded every two days.
  • DMSO dimethyl sulfoxide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及一种炔苯基苯酰胺类化合物及其应用。本发明的炔苯基苯酰胺类化合物具有式(I)所示结构，该类化合物可作为蛋白激酶抑制剂，能够有效抑制TRK蛋白激酶的活性并且能抑制多种肿瘤细胞的增殖、迁移和侵袭，同时具有较好的药代动力学和毒性低的特点。

Description

炔苯基苯酰胺类化合物及其应用 技术领域
本发明涉及化学医药技术领域，特别是涉及一种炔苯基苯酰胺类化合物及其应用。
背景技术
原肌球蛋白受体激酶TRK(tropomyosin receptor kinase)，属于受体酪氨酸激酶家族(receptor tyrosine kinase，RTK)，它有三个亚型：TRKA、TRKB、TRKC，分别由NTRK1、NTRK2、NTRK3基因编码。TRK是一类跨膜蛋白，由胞外的配体结合区、跨膜区(transmembrane domain,TM)和胞内区组成，TRK主要通过结合神经营养因子(Neurotrophic factors,NTs)发挥作用。神经营养因子是一类由神经所支配的组织(如肌肉)和星形胶质细胞产生的且为神经元生长与存活所必需的一类蛋白质分子。目前主要发现了四种神经营养因子，它们分别是NGF(神经生长因子)、脑源性神经营养因子(BDNF)、神经营养因子3(NT-3)和神经营养因子4(NT-4)，其中NGF与TRKA结合，BDNF和NT-4与TRKB结合，NT-3可以与三种TRK蛋白结合，但其与TRKC的结合能力更强。当受到信号诱导而活化时，TRK通过自身二聚化和磷酸化，依次激活下游的信号通路实现各种细胞生理功能。TRK的下游信号通路包括MAPK、PI3K/AKT、PLCγ/PKC通路，这些信号通路调节着细胞的增殖、分化、迁移、凋亡等生理过程，以及神经突触的弹性、神经树突的长出修复、神经元降解的预防和修复以及感觉神经元的维护等与神经元相关的多种生理活动。
大量研究表明，TRK的过量表达、基因融合以及单核苷酸改变与多种类型的肿瘤发生发展密切相关，如非小细胞肺癌、乳腺癌、结肠癌、前列腺癌、甲状腺癌、恶性黑色素瘤、神经母细胞瘤和乳腺样分泌癌等。在TRK异常激活的机制中，最普遍的机制是TRK的基因融合。医学研究最早发现的NTRK融合基因是在结肠癌样本中发现的TPM3-NTRK1融合基因，随着研究的深入，研究人员又陆续发现了CD74-NTRK1、ETV6-NTRK2、QKI-NTRK2、ETV6-NTRK3等多种类型的融合基因。NTRK融合基因所表达的TRK融合蛋白可以在不依赖与配体结合的情况下持续性激活下游信号通路，从而诱导细胞异常增殖，促进肿瘤的发生与发展。因此，TRK被视为是一个有效的抗癌治疗靶点。
目前已有一款由美国LOXO公司开发的TRK选择性抑制剂Larotrectinib于2018年由FDA批准上市，由罗氏制药公司开发的TRK抑制剂Entrectinib于2019年6月在日本上市，由TESARO公司开发的的Belizatinib正在进行临床研究，此外Cabozanitinib、Sitravatinib、Altiratinib等多靶点抑制剂也具有良好的TRK抑制活性。
持续使用TRK抑制剂而引起的NTRK基因点突变是导致肿瘤产生耐药的关键原因。临床研究已经陆续发现了NTRK1的G595R、G667C、F589L、G667S以及NTRK3的G623R、G696A突变，目前还没有针对这些突变的抑制剂上市，TRK二代抑制剂LOXO-195、TPX-0005和ONO-5390556正处于临床研究中。
发明内容
基于此，本发明提供了一种炔苯基苯酰胺类化合物或其药学上可接受的盐或其立体异构体，该类化合物可作为蛋白激酶抑制剂，能够有效抑制TRK蛋白激酶的活性并且能抑制多种肿瘤细胞的增殖、迁移和侵袭，尤其还具有很好的药代动力学性质和抗耐药性。
具体技术方案如下：
具有式(I)结构的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子；
Figure PCTCN2021117495-appb-000001
其中，R 1任选自：C 1～C 20烷基；
R 2任选自：H、卤素、C 1～C 20烷基、C 1～C 20烷氧基或卤素取代的C 1～C 20烷基；
R 3任选自：H、氟取代的C 1～C 4烷基、取代或未取代的含1-3个N环原子的5-6元杂环基；
R 4任选自：H、卤素、硝基、取代或未取代的C 1～C 20烷基、取代或未取代的C 1～C 20烷氧基、取代或未取代的含1-3个N环原子的5-10元杂环基、取代或未取代的含1-3个N环原子的5-10元杂芳基；
R 5为-NR 6R 7；
其中，R 6、R 7分别独立地选自：-(CH 2) mNR 8R 9、-(CH 2) nCR 10R 11R 12、-(CH 2) pOR 12，或者R 6、R 7与它们所连接的氮原子一起形成被取代或未被取代的含有杂原子的单环、稠环、螺环或桥环；
R 8、R 9分别独立地选自：H、C 1～C 20烷基；或者R 8、R 9与它们所连接的氮原子一起形成被取代或未被取代的含有1-3个杂原子的单环、稠环、螺环或桥环；
R 10、R 11与它们所连接的碳原子一起形成被取代或未被取代的含有1-3个杂原子的单环、稠环、螺环或桥环；
R 12选自：H、C 1～C 20烷基；
m、n、p分别独立地选自：0-10的整数。
在其中一些实施例中，R 4任选自：H、卤素、硝基、C 1～C 10烷基、卤素取代的C 1～C 10烷基、C 1～C 10烷氧基、卤素取代的C 1～C 10烷氧基、-(CH 2) xNR 17R 18、被1-5个R 19代或未被取代的含有1-3个N环原子的5-10元杂环基、被1-5个R 19取代或未被取代的含有1-3个N环原子的5-10元杂芳基；x＝1-5的整数；
R 17、R 18与它们所连接的氮原子一起形成被1-5个R 19取代或未被取代的吗啉基、吡咯烷基、哌啶基或哌嗪基；
各R 19分别独立地选自C 1-C 5烷基。
在其中一些实施例中，R 4任选自：H、卤素、硝基、C 1～C 8烷基、卤素取代的C 1～C 8烷基、C 1～C 8烷氧基、卤素取代的C 1～C 8烷氧基、-(CH 2) xNR 17R 18、被1-5个R 19取代或未被取代的含有1-3个N环原子的5-6元杂环基、被1-5个R 19取代或未被取代的含有1-3个N环原子的5-6元杂芳基；x为1-5的整数。
在其中一些实施例中，R 4任选自：H、卤素、硝基、C 1～C 4烷基、卤素取代的C 1～C 4烷基、C 1～C 4烷氧基、卤素取代的C 1～C 4烷氧基、-(CH 2) xNR 17R 18、被1-3个R 19取代或未被取代的含有1-3个N环原子的5-6元杂环基、被1-3个R 19取代或未被取代的含有1-3个N环原子的5-6元杂芳基；x＝1-5的整数。
在其中一些实施例中，R 4任选自：H、卤素、硝基、C 1～C 4烷基、卤素取代的C 1～C 4烷基、C 1～C 4烷氧基、卤素取代的C 1～C 4烷氧基、-(CH 2) xNR 17R 18、被1-3个R 19取代或未被取代的咪唑基；x为1、2或3；
R 17、R 18与它们所连接的氮原子一起形成被1-3个R 19取代或未被取代的哌嗪基；
各R 19分别独立地选自：C 1-C 5烷基。
在其中一些实施例中，R 4任选自：H、卤素、硝基、甲基、乙基、丙基、甲氧基、乙氧基、丙氧基、三氟甲基、三氟乙基、
Figure PCTCN2021117495-appb-000002
各R 19分别独立地选自：甲基、乙基、丙基。
在其中一些实施例中，R 6、R 7分别独立地选自：-(CH 2) mNR 8R 9、-(CH 2) nCR 10R 11R 12、-(CH 2) pOR 12，或者R 6、R 7与它们所连接的氮原子一起形成被1-5个R 13取代或未被取代的含有1-3个杂原子的3-15元单环、稠环、螺环或桥环，杂原子选自：O、N、S；
R 8、R 9分别独立地选自：H、C 1～C 5烷基；或者R 8、R 9与它们所连接的氮原子一起形成被1-5个R 13取代或未被取代的含有1-3个杂原子的3-10元单环、稠环、螺环或桥环，杂原子选自：O、N；
R 10、R 11与它们所连接的碳原子一起形成被1-5个R 13取代或未被取代的含有1-3个杂原子的3-10元单环、稠环、螺环或桥环，杂原子选自：O、N；
R 12选自：H、C 1-C 5烷基；
各R 13分别独立地选自：H、C 1-C 5烷基、C 1-C 5烷酰基、羟基、羟基取代的C 1-C 5烷基、氨基取代的C 1-C 5烷基、氨基取代的C 1-C 5烷氧基、C 3-C 7环烷基取代的C 1-C 3烷基、-NR 15R 16、被1-5个R 14取代或未被取代的含有1-3个杂原子的3-10元单环、稠环、螺环或桥环，杂原子选自：O、N；
R 14、R 15、R 16分别独立地选自：H、C 1-C 5烷基；
m、n、p分别独立地选自：0-5的整数。
在其中一些实施例中，R 6、R 7分别独立地选自：-(CH 2) mNR 8R 9、-(CH 2) pOR 12，或者R 6、R 7与它们所连接的氮原子一起形成被1-3个R 13取代或未被取代的吗啉基、吡咯烷基、哌啶基或者哌嗪基；
R 8、R 9分别独立地选自：H、C 1～C 5烷基，或者R 8、R 9与它们所连接的氮原子一起形成被1-5个R 13取代或未被取代的吗啉基、吡咯烷基、哌啶基或哌嗪基；
R 12选自：H、C 1-C 5烷基；
各R 13分别独立地选自：H、C 1-C 5烷基、C 1-C 5烷酰基、羟基、-NR 15R 16、被1-2个R 14取代或未被取代的氧杂环丁基、被1-4个R 14取代或未被取代的吗啉基；
R 14、R 15、R 16分别独立地选自：H、C 1-C 3烷基；
m、p分别独立地选自：1、2、3、4或5。
在其中一些实施例中，R 5选自以下任意一种基团：
Figure PCTCN2021117495-appb-000003
Figure PCTCN2021117495-appb-000004
在其中一些实施例中，R 4为卤素；R 5为-NR 6R 7；
R 6、R 7分别独立地选自：-(CH 2) mNR 8R 9、-(CH 2) pOR 12，或者R 6、R 7与它们所连接的氮原子一起形成被1-3个R 13取代或未被取代的吗啉基、吡咯烷基、哌啶基或者哌嗪基；
R 8、R 9分别独立地选自：H、C 1-C 3烷基，或者R 8、R 9与它们所连接的氮原子一起形成被1-2个R 13取代或未被取代的吗啉基、吡咯烷基、哌啶基或哌嗪基；
R 12选自：H、C 1-C 3烷基；
各R 13分别独立地选自：H、C 1-C 3烷基、乙酰基、羟基、-NR 15R 16、氧杂环丁基、吗啉基；
R 15、R 16分别独立地选自：H、C 1-C 3烷基；
m、p分别独立地选自：2、3或4。
在其中一些实施例中，R 4为Cl，
R 5选自：
Figure PCTCN2021117495-appb-000005
Figure PCTCN2021117495-appb-000006
在其中一些实施例中，R 4选自：H、卤素、甲基、甲氧基、三氟甲基、硝基、
Figure PCTCN2021117495-appb-000007
R 5为
Figure PCTCN2021117495-appb-000008
在其中一些实施例中，R 4选自：H、
Figure PCTCN2021117495-appb-000009
R 5选自：
Figure PCTCN2021117495-appb-000010
在其中一些实施例中，R 4为
Figure PCTCN2021117495-appb-000011
R 5选自：
Figure PCTCN2021117495-appb-000012
在其中一些实施例中，R 1任选自：C 1～C 10烷基。
在其中一些实施例中，R 1任选自：C 1～C 4烷基。
在其中一些实施例中，R 1任选自：甲基、乙基、异丙基、叔丁基。
在其中一些实施例中，R 2任选自：H、卤素、C 1～C 10烷基、卤素取代的C 1～C 10烷基。
在其中一些实施例中，R 2任选自：H、卤素、C 1～C 4烷基、卤素取代的C 1～C 4烷基、C 1～C 4烷氧基。
在其中一些实施例中，R 2任选自：氢、氟、甲基、乙基、异丙基、叔丁基、二氟甲基、二氟乙基、三氟甲基或三氟乙基。
在其中一些实施例中，R 3选自：H、二氟甲基、二氟乙基、三氟甲基或三氟乙基。
在其中一些实施例中，所述炔苯基苯酰胺类化合物具有式(II)所示结构：
Figure PCTCN2021117495-appb-000013
本发明的另一目的是提供一种上述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子在制备TRK抑制剂中的应用。
本发明的另一目的是提供一种上述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子在制备预防和/或治疗由TRK酪氨酸激酶介导的疾病的药物中的应用。
在其中一些实施例中，所述由TRK酪氨酸激酶介导的疾病为肿瘤，优选为非小细胞肺癌、乳腺癌、结肠癌、前列腺癌、甲状腺癌、恶性黑色素瘤、神经母细胞瘤或乳腺样分泌癌。
本发明的再一目的是提供一种预防和/或治疗肿瘤的药用组合物，包括活性成分和药学上可接受的辅料，所述活性成分包括上述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子。
本发明提供的炔苯基苯酰胺类化合物，对TRKs激酶有很强的抑制活性，并且对Ba/F3-TRKs稳定株的野生型及耐药型细胞增殖有很强的抑制活性。可以用于制备预防或者治疗由TRK酪氨酸激酶介导的疾病的药物，比如非小细胞肺癌、乳腺癌、结肠癌、前列腺癌、甲状腺癌、恶性黑色素瘤、神经母细胞瘤和乳腺样分泌癌等，同时还具有很好的药代动力学和毒性低的特点。
附图说明
图1为化合物XS3-55的体内抗肿瘤活性。
图2为化合物XS3-55对老鼠体重的影响。
具体实施方式
本发明下列实施例中未注明具体条件的实验方法，通常按照常规条件，或按照制造厂商所建议的条件。实施例中所用到的各种常用化学试剂，均为市售产品。
除非另有定义，本发明所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本发明的说明书中所使用的术语只是为了描述具体的实施例的目的，不用于限制本发明。
本发明的术语“包括”和“具有”以及它们任何变形，意图在于覆盖不排他的包含。例如包含了一系列步骤的过程、方法、装置、产品或设备没有限定于已列出的步骤或模块，而是可选地还包括没有列出的步骤，或可选地还包括对于这些过程、方法、产品或设备固有的其它步骤。
在本发明中提及的“多个”是指两个或两个以上。“和/或”，描述关联对象的关联关系，表示可以存在三种关系，例如，A和/或B，可以表示：单独存在A，同时存在A和B，单独存在B这三种情况。字符“/”一般表示前后关联对象是一种“或”的关系。
本发明所述化合物中，当任何变量(例如R 10、R 11等)在任何组分中出现超过一次，则其每次出现的定义独立于其它每次出现的定义。同样，允许取代基及变量的组合，只要这种组合使化合物稳定。自取代基划入环系统的线表示所指的键可连接到任何能取代的环原子上。如果环系统为多环，其意味着这种键仅连接到邻近环的任何适当的碳原子上。要理解本领域普通技术人员可选择本发明化合物的取代基及取代型式而提供化学上稳定的并可通过本领域技术和下列提出的方法自可容易获得的原料容易合成的化合物。如果取代基自身被超过一个基团取代，应理解这些基团可在相同碳原子上或不同碳原子上，只要使结构稳定。
本文所用术语“烷基”意指包括具有特定碳原子数目的支链的和直链的饱和脂肪烃基。例如，“C 1-C 20烷基”中“C 1-C 20”的定义包括以直链或支链排列的具有1、2、3、4、5、……或20个碳原子的基团。术语“环烷基”指具有特定碳原子数目的单环饱和脂肪烃基。例如“C 3～C 7环烷基”包括环丙基、环丁基、环戊基、环己基、环庚基等。
本文所用术语“烷氧基”指烷基与氧直接连接的基团，即具有-O-烷基结构的基团，如-OCH 3、-OCH 2CH 3、-OCH 2CH 2CH 3、-O-CH 2CH(CH 3) 2、-OCH 2CH 2CH 2CH 3、-O-CH(CH 3) 2等。
本文所用术语“杂环基”是指含有1个或多个选自O、N和S的杂原子的非芳香性杂环基团，例如：哌啶基，四氢吡咯基(吡咯烷基)、吗啉基、哌嗪基等。杂环取代基的连接可以通过碳原子或通过杂原子实现。
本文所用术语“杂芳基”指含有1个或多个选自O、N或S的杂原子的芳香环，本发明范围内的杂芳基包括但不限于：喹啉基、吡唑基、吡咯基、噻吩基、呋喃基、吡啶基、嘧啶基、吡嗪基、三氮唑基、咪唑基、恶唑基、异恶唑基、哒嗪基、苯并呋喃基、苯并噻吩基、苯并恶唑、吲哚基等；“杂芳基”也理解为包括任何含有氮的杂芳基的N-氧化物衍生物。杂芳基的连接可以通过碳原子或通过杂原子实现。
本文所用术语“取代的”是指用指定取代基的基团置换特定结构中的氢基。
正如本领域技术人员所理解的，本文中所用“卤素”意指包括氯、氟、溴和碘。
本发明包括式(I)或式(II)化合物的游离形式，也包括其药学上可接受的盐、其立体异构 体及其前药分子。术语“游离形式”指以非盐形式的化合物。包括在内的药学上可接受盐不仅包括本文所述特定化合物的示例性盐，也包括所有式(I)或式(II)化合物游离形式的典型的药学上可接受的盐。可使用本领域已知技术分离所述化合物特定盐的游离形式。例如，可通过用适当的碱稀水溶液例如NaOH稀水溶液、碳酸钾稀水溶液、稀氨水及碳酸氢钠稀水溶液处理该盐使游离形式再生。游离形式在某些物理性质例如在极性溶剂中溶解度上与其各自盐形式多少有些区别，但是为发明的目的这种酸盐及碱盐在其它药学方面与其各自游离形式相当。
可通过常规化学方法自含有碱性部分或酸性部分的本发明化合物合成本发明的药学上可接受的盐。通常，通过离子交换色谱或通过游离碱和化学计算量或过量的所需盐形式的无机或有机酸在适当溶剂或多种溶剂的组合中反应制备碱性化合物的盐。类似的，通过和适当的无机或有机碱反应形成酸性化合物的盐。
因此，本发明化合物的药学上可接受的盐包括通过碱性本发明化合物和无机或有机酸反应形成的本发明化合物的常规无毒盐。例如，常规的无毒盐包括得自无机酸例如盐酸、氢溴酸、硫酸、氨基磺酸、磷酸、硝酸等制备的盐，也包括得自有机酸例如乙酸、丙酸、琥珀酸、乙醇酸、硬脂酸、乳酸、苹果酸、酒石酸、柠檬酸、抗坏血酸、扑酸、马来酸、羟基马来酸、苯乙酸、谷氨酸、苯甲酸、水杨酸、对氨基苯磺酸、2-乙酰氧基一苯甲酸、富马酸、苯磺酸、甲苯磺酸、甲磺酸、乙烷二磺酸、草酸、羟乙基磺酸、三氟乙酸等制备的盐。
如果本发明化合物为酸性的，则适当的“药学上可接受的盐”指通过药学上可接受的无毒碱包括无机碱及有机碱制备的盐。得自无机碱的盐包括铝盐、铵盐、钙盐、铜盐、铁盐、亚铁盐、锂盐、镁盐、锰盐、亚锰盐、钾盐、钠盐、锌盐等。特别优选铵盐、钙盐、镁盐、钾盐和钠盐。得自药学上可接受的有机无毒碱的盐，所述碱包括伯胺、仲胺和叔胺的盐，取代的胺包括天然存在的取代胺、环状胺及碱性离子交换树脂例如精氨酸、甜菜碱、咖啡因、胆碱、N,N'-二苄基乙二胺、二乙胺、2-二乙基氨基乙醇、2-二甲基氨基乙醇、氨基乙醇、乙醇胺、乙二胺、N-乙基吗啉、N-乙基哌啶、葡萄糖胺、氨基葡萄糖、组氨酸、羟钴胺、异丙基胺、赖氨酸、甲基葡萄糖胺、吗啉、哌嗪,哌啶、呱咤、多胺树脂、普鲁卡因、嘌呤、可可碱、三乙胺、三甲胺、三丙胺、氨基丁三醇等。
Berg等，“Pharmaceutical Salts”J.Pharm.Sci.’1977：66：1-19更详细描述了上文所述药学上可接受的盐及其它典型的药学上可接受的盐的制备。
以下结合具体实施例对本发明作进一步详细的说明。
实施例1：3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-2-甲基-N-(3-((4-甲基哌嗪-1-基)甲 基)-5-(三氟甲基)苯基)苯甲酰胺(命名为XS116)的制备
Figure PCTCN2021117495-appb-000014
步骤1：2-甲基-3-((三甲基甲硅烷基)乙炔基)苯甲酸甲酯(化合物2)的制备
Figure PCTCN2021117495-appb-000015
500mL三颈瓶中，加入化合物1 10g(36mmol)，碘化亚铜689mg(3.6mmol)，二(三苯基膦)二氯化钯1.27g(1.8mmol)，无水乙腈150mL，N,N-二异丙基乙胺9.3g(72mmol)，置换氩气，封闭反应体系，然后用注射器注入三甲基硅乙炔10.6g(108mmol)，60℃搅拌6小时。用硅藻土过滤反应液，旋干溶剂得到黑色混合物，直接用于下一步反应。
步骤2：2-乙炔基-2-甲基苯甲酸甲酯(化合物3)的制备
Figure PCTCN2021117495-appb-000016
将上一步粗产品用甲醇溶解，加入约20mL的1mol/L四丁基氟化铵的四氢呋喃溶液，常温搅拌2小时。旋干反应体系，柱层析得到黄棕色油状物4g(两步总产率63％)。
1H NMR(400MHz,DMSO-d 6)δ7.80(s,1H),7.78(s,1H),7.58(s,1H),4.27(s,1H),3.85(s,3H),2.37(s,3H).LC-MS(ESI)m/z 175.5[M+H] +.
步骤3：3-乙炔基-2-甲基苯甲酸(化合物4)的制备
Figure PCTCN2021117495-appb-000017
将化合物3 1.5g(9mmol)溶于体积比为10：1：5的四氢呋喃、甲醇和水的混合溶剂中，然后加入氢氧化锂的水合物1.8g(40mmol)，60℃搅拌1小时。过滤，旋干反应体系，然后加入4M盐酸溶液直至体系呈酸性，此时有白色固体析出，过滤收集白色固体，干燥，得到白色固体900mg(产率65％)。
1H NMR(400MHz,DMSO-d6)δ13.09(s,1H),7.77(dd,J＝7.8,0.9Hz,1H),7.62(d,J＝7.6Hz,1H),7.29(t,J＝7.7Hz,1H),4.47(s,1H),2.61(s,3H).LC-MS(ESI)m/z 158.9[M-H] -.
步骤4：3-乙炔基-2-甲基-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)苯甲酰胺(化合物6)的制备
Figure PCTCN2021117495-appb-000018
将化合物4 2.3g，化合物5 3.4g溶于40mL的N,N-二甲基甲酰胺(DMF)中，加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)9.12g(24mmol)，N,N-二异丙基乙胺2.3g(18mmol)。70℃加热搅拌2小时。旋干反应体系，加水，用乙酸乙酯萃取，水洗，无水硫酸钠干燥，旋干溶剂，柱层析得到黄色油状物3.4g(产率70％)。
1H NMR(400MHz,DMSO-d 6)δ10.52(s,1H),8.17(s,1H),8.10(s,1H),8.00(d,J＝8.0Hz,1H),7.91(m,1H),7.47(d,J＝8.0Hz,1H),7.34(s,1H),4.51(s,1H),3.53(s,2H),2.46(s,3H),2.39(s,4H),2.33(s,4H),2.15(s,3H).LC-MS(ESI)m/z 416.3[M+H] +.
步骤5：3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-2-甲基-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)苯甲酰胺(XS116)的制备
Figure PCTCN2021117495-appb-000019
将化合物6 210mg(0.51mmol)和化合物7 120mg(0.61mmol)溶于10mL无水N,N-二甲基甲酰胺(DMF)中，然后加入碘化亚铜19mg(0.1mmol)，二(三苯基膦)二氯化钯35mg(0.05mmol)，N,N-二异丙基乙胺131mg(1.02mmol)，置换氩气，封闭反应体系。80℃加热搅拌，过夜反应。用硅藻土过滤，旋干滤液，柱层析得到黄白色固体70mg(产率26％)。
1H NMR(400MHz,Chloroform-d)δ8.50(dd,J＝4.4,1.6Hz,1H),8.07(s,1H),8.02(dd,J＝9.2,1.7Hz,1H),7.94(s,1H),7.81(d,J＝4.5Hz,2H),7.73(dd,J＝7.7,1.4Hz,1H),7.50(d,J＝7.8Hz,1H),7.41(s,1H),7.32(t,J＝7.7Hz,1H),7.16(dd,J＝9.2,4.4Hz,1H),3.62(s,2H),2.76(s,3H),2.64(s,8H),2.41(s,3H).LC-MS(ESI)m/z 533.3[M+H] +.
实施例2：3-(咪唑并[1,2-a]嘧啶-3-基乙炔基)-2-甲基-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)苯甲酰胺(命名为XS2-161)的制备
Figure PCTCN2021117495-appb-000020
合成方法如实施例1。
1H NMR(400MHz,Chloroform-d)δ9.06(s,1H),8.64(dd,J＝4.1,2.0Hz,1H),8.60(dd,J＝6.8,2.0Hz,1H),8.12(s,1H),8.03(s,1H),7.90(s,1H),7.58(dd,J＝7.8,1.3Hz,1H),7.50(dd,J＝7.8,1.3Hz,1H),7.40(s,1H),7.25(t,J＝7.7Hz,1H),7.09(dd,J＝6.8,4.1Hz,1H),3.70(s,2H),3.11(q,J＝7.3Hz,4H),2.91(d,J＝5.0Hz,4H),2.73(s,3H),2.61(s,3H).LC-MS(ESI)m/z533.2[M+H] +.
实施例3:3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-2-甲基-N-(3-(三氟甲基)苯基)苯甲酰胺(命名为XS2-106)的制备
Figure PCTCN2021117495-appb-000021
步骤1:3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-2-甲基苯甲酸甲酯(化合物3)的制备
Figure PCTCN2021117495-appb-000022
将化合物1 2.5g(14mmol)和化合物2 3.4g(17mmol)溶于40mL无水N,N-二甲基甲酰胺(DMF)中，然后加入碘化亚铜533mg(2.8mmol)，二(三苯基膦)二氯化钯982mg(1.4mmol)，N,N-二异丙基乙胺3.6g(28mmol)，置换氩气，封闭反应体系。80℃加热搅拌，过夜反应。用硅藻土过滤，旋干滤液，柱层析得到黄色粉末状固体1.38g(收率34％)。
1H NMR(400MHz,DMSO-d6)δ8.74(d,J＝4.3Hz,1H),8.27(d,J＝8.9Hz,2H),7.83(d,J＝7.7Hz,1H),7.75(d,J＝7.5Hz,1H),7.44–7.41(m,1H),7.39(d,J＝7.6Hz,1H),3.85(s,3H)，2.76(s,3H).LC-MS(ESI)m/z 292.3[M+H] +.
步骤2：3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-2-甲基苯甲酸(化合物4)
Figure PCTCN2021117495-appb-000023
将化合物3 1.38g(4.7mmol)溶于体积比为10：1：5的四氢呋喃、甲醇和水的混合溶剂中，然后加入氢氧化锂的水合物995mg(24mmol)，60℃搅拌1小时。过滤，旋干反应体系，然后加入4M盐酸溶液直至体系呈酸性，此时有固体析出，过滤收集固体，干燥，得到黄色固体1.05g(收率81％)。
1H NMR(400MHz,DMSO-d 6)δ13.14(s,1H),8.72(d,J＝3.9Hz,1H),8.32–8.19(m,2H),7.83(d,J＝7.6Hz,1H),7.75(d,J＝7.3Hz,1H),7.44–7.34(m,2H),2.76(s,3H).LC-MS(ESI)m/z 276.8[M-H] -.
步骤3：3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-2-甲基-N-(3-(三氟甲基)苯基)苯甲酰胺(XS2-106)
Figure PCTCN2021117495-appb-000024
将化合物4 100mg(0.36mmol)，化合物5 48mg(0.3mmol)溶于10mL的N,N-二甲基甲酰胺(DMF)中，加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)137mg(0.36mmol),N,N-二异丙基乙胺77mg(0.6mmol)。80摄氏度加热搅拌，过夜反应。旋干反应体系，柱层析得到黄白色固体51mg(收率40％)。
1H NMR(400MHz,Chloroform-d)δ8.51(d,J＝4.1Hz,1H),8.03(dd,J＝23.3,14.3Hz,3H),7.89(d,J＝7.4Hz,1H),7.73(d,J＝6.6Hz,2H),7.50(ddd,J＝24.8,16.6,7.8Hz,3H),7.32(t,J＝7.7Hz,1H),7.17(dd,J＝9.1,4.4Hz,1H),2.76(s,3H).LC-MS(ESI)m/z 419.2[M-H] -.
实施例4:N-(3-氟-5-(三氟甲基)苯基)-3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-2-甲基苯甲酰胺(命名为XS2-109)的制备
Figure PCTCN2021117495-appb-000025
合成方法如实施例3。
1H NMR(400MHz,Chloroform-d)δ8.53(d,J＝4.2Hz,1H),8.08(s,2H),7.91(d,J＝10.1Hz,1H),7.81(s,1H),7.74(d,J＝7.8Hz,1H),7.59(s,1H),7.50(d,J＝7.5Hz,1H),7.33(t,J＝7.7 Hz,1H),7.19(s,1H),7.16(d,J＝8.2Hz,1H),2.75(s,3H).LC-MS(ESI)m/z 437.6[M-H] -.
实施例5:N-(3-氯-5-(三氟甲基)苯基)-3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-2-甲基苯甲酰胺(命名为XS2-112)的制备
Figure PCTCN2021117495-appb-000026
合成方法如实施例3。
1H NMR(400MHz,Chloroform-d)δ8.50(dd,J＝4.4,1.5Hz,1H),8.06(d,J＝4.2Hz,2H),8.01(dd,J＝9.2,1.6Hz,1H),7.85(s,1H),7.80(s,1H),7.74(d,J＝6.7Hz,1H),7.48(d,J＝6.9Hz,1H),7.44(s,1H),7.32(t,J＝7.7Hz,1H),7.16(dd,J＝9.2,4.4Hz,1H),2.75(s,3H).LC-MS(ESI)m/z 455.5[M+H] +.
实施例6:2-甲基-3-((6-吗啉代咪唑并[1,2-b]哒嗪-3-基)乙炔基)-N-(3-(三氟甲基)苯基)苯甲酰胺(命名为XS3-23)的制备
Figure PCTCN2021117495-appb-000027
步骤1:3-乙炔基-2-甲基-N-(3-(三氟甲基)苯基)苯甲酰胺(化合物3)制备的
Figure PCTCN2021117495-appb-000028
将化合物1 120mg(0.74mmol)，化合物2 101mg(0.62mmol)溶于15mL的N,N-二甲基甲酰胺(DMF)中，加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU) 353mg(0.93mmol)，N,N-二异丙基乙胺160mg(1.24mmol)。80℃加热搅拌2小时。旋干反应体系，加水，用乙酸乙酯萃取，水洗，无水硫酸钠干燥，旋干溶剂，柱层析得到黄色油状物150mg(收率80％)。
1H NMR(400MHz,DMSO-d 6)δ10.75(s,1H),8.26(d,J＝2.0Hz,1H),7.95–7.90(m,1H),7.63–7.58(m,2H),7.53(dd,J＝7.7,1.4Hz,1H),7.49–7.45(m,1H),7.35(t,J＝7.7Hz,1H),4.52(s,1H)，2.47(s,3H).LC-MS(ESI)m/z 304.1[M+H] +.
步骤2：4-(3-碘咪唑并[1,2-b]哒嗪-6-基)吗啉(化合物5)的制备
Figure PCTCN2021117495-appb-000029
将化合物4 300mg(1.07mmol)溶于15mL的二甲基亚砜(DMSO)中，加入吗啉280mg(3.22mmol)，氟化钾744mg(12.84mg)。120℃加热搅拌3小时。过滤，旋干反应体系，柱层析得到黄色粉末状固体260mg(收率74％)。
1H NMR(400MHz,Chloroform-d)δ7.70(d,J＝9.8Hz,1H),7.64(s,1H),6.82(d,J＝9.9Hz,1H),3.89(t,J＝4.8Hz,4H),3.57(t,J＝4.9Hz,4H).LC-MS(ESI)m/z 331.0[M+H] +.
步骤3：2-甲基-3-((6-吗啉代咪唑并[1,2-b]哒嗪-3-基)乙炔基)-N-(3-(三氟甲基)苯基)苯甲酰胺(XS3-23)的制备
Figure PCTCN2021117495-appb-000030
将化合物3 138mg(0.45mmol)和化合物5 300mg(0.91mmol)溶于10mL无水N,N-二甲基甲酰胺(DMF)中，然后加入碘化亚铜7mg(0.036mmol)，三二亚苄基丙酮二钯21mg(0.023mmol)，三叔丁基磷9mg(0.045mmol)，碳酸钾124mg(0.9mmol)，置换氩气，封闭反应体系。80℃加热搅拌，过夜反应。用硅藻土过滤，旋干滤液，柱层析得到黄白色固体120mg(收率52％)。
1H NMR(400MHz,Chloroform-d)δ8.06–7.98(m,2H),7.91(d,J＝8.1Hz,1H),7.87–7.74(m,2H),7.64(d,J＝7.7Hz,1H),7.54(t,J＝8.0Hz,1H),7.47(d,J＝6.5Hz,2H),7.30(d,J＝7.6Hz,1H),6.90(d,J＝9.5Hz,1H),3.87(t,J＝4.7Hz,4H),3.57(t,J＝4.8Hz,4H),2.73(s,3H).LC-MS(ESI)m/z 504.2[M-H] -.
实施例7：N-(3-氯-5-(三氟甲基)苯基)-2-甲基-3-((6-吗啉代咪唑并[1,2-b]哒嗪-3-基)乙炔基)苯甲酰胺(命名为XS3-61)的制备
Figure PCTCN2021117495-appb-000031
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.92(s,1H),8.13(d,J＝2.5Hz,2H),7.98(d,J＝10.0Hz,2H),7.70(dd,J＝7.7,1.4Hz,1H),7.61(s,1H),7.56(dd,J＝7.7,1.4Hz,1H),7.42(t,J＝7.7Hz,1H),7.32(d,J＝9.8Hz,1H),3.74(t,J＝4.8Hz,4H),3.53(t,J＝4.8Hz,4H),2.63(s,3H).LC-MS(ESI)m/z 539.8[M+H] +.
实施例8：N-(3-氟-5-(三氟甲基)苯基)-2-甲基-3-((6-甲基咪唑吡嗪-3-基-3-基)苯甲酰胺(命名为XS4-80)的制备
Figure PCTCN2021117495-appb-000032
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.94(s,1H),8.02–7.96(m,2H),7.96–7.89(m,2H),7.70(dd,J＝7.8,1.4Hz,1H),7.55(dd,J＝7.8,1.4Hz,1H),7.42(dd,J＝8.9,6.3Hz,2H),7.31(d,J＝10.0Hz,1H),3.74(t,J＝4.8Hz,4H),3.53(t,J＝4.8Hz,4H),2.63(s,3H).HRMS(ESI)for C 27H 21F 4N 5O 2[M+H] +:calcd 524.1704,found 524.1686.
实施例9：2-甲基-N-(3-甲基-5-(三氟甲基)苯基)-3-((6-甲基-1,2-B]哒嗪-3-基)苯甲酰胺(命名为XS4-81)的制备
Figure PCTCN2021117495-appb-000033
合成方法如实施例6。 1H NMR(400MHz,DMSO-d 6)δ10.68(s,1H),8.05–7.90(m,3H),7.80(s,1H),7.68(dd,J＝7.7,1.4Hz,1H),7.52(dd,J＝7.7,1.4Hz,1H),7.40(t,J＝7.7Hz,1H),7.34–7.28(m,2H),3.74(dd,J＝5.8,3.9Hz,4H),3.53(t,J＝4.8Hz,4H),2.62(s,3H),2.40(s,3H).HRMS(ESI)for C 28H 24F 3N 5O 2[M+H] +:calcd 520.1955,found 520.1939.
实施例10：N-(3-甲氧基-5-(三氟甲基)苯基)-2-甲基-3-((6-甲基咪唑吡嗪-3-基-3-基)苯甲酰胺(命名为XS4-72)的制备
Figure PCTCN2021117495-appb-000034
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.72(s,1H),7.97(d,J＝9.9Hz,1H),7.93(s,1H),7.81(s,1H),7.68(dd,J＝7.8,1.4Hz,1H),7.62(t,J＝2.2Hz,1H),7.53(dd,J＝7.8,1.4Hz,1H),7.41(t,J＝7.7Hz,1H),7.31(d,J＝9.9Hz,1H),7.01(t,J＝2.0Hz,1H),3.84(s,3H),3.74(dd,J＝5.8,3.8Hz,4H),3.53(t,J＝4.8Hz,4H),2.62(s,3H).HRMS(ESI)for C 27H 21ClF 3N 5O 2[M+H] +:calcd 536.1904,found 536.1919.
实施例11：N-(3,5-双(三氟甲基)苯基)-2-甲基-3-((6-甲基咪唑吡嗪-3-基-3-基)苯甲酰胺(命名为XS4-76)的制备
Figure PCTCN2021117495-appb-000035
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ11.07(s,1H),8.44(s,2H),7.98(d,J＝10.0Hz,2H),7.85(s,1H),7.71(dd,J＝7.8,1.4Hz,1H),7.59(dd,J＝7.8,1.4Hz,1H),7.43(t,J＝7.7Hz,1H),7.32(d,J＝9.5Hz,1H),3.74(t,J＝4.8Hz,4H),3.53(t,J＝4.8Hz,4H),2.64(s,3H).HRMS(ESI)for C 28H 21F 6N 5O 2[M+H] +:calcd 574.1672,found 574.1676.
实施例12：2-甲基-3-((6-甲基咪唑吡嗪-3-基)乙炔基)-N-(3-硝基-5-(三氟甲基)苯基)苯甲酰胺(命名为XS4-77)的制备
Figure PCTCN2021117495-appb-000036
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ11.20(s,1H),8.95(t,J＝2.1Hz,1H),8.53(s,1H),8.23(d,J＝2.1Hz,1H),7.97(d,J＝9.9Hz,1H),7.93(s,1H),7.72(dd,J＝7.8,1.4Hz,1H),7.60(dd,J＝7.7,1.4Hz,1H),7.44(t,J＝7.7Hz,1H),7.31(dd,J＝10.1,1.6Hz,1H),3.74(t,J＝4.8Hz,4H),3.53(t,J＝4.9Hz,4H),2.65(s,3H).HRMS(ESI)for C 27H 21F 3N 6O 4[M+H] +:calcd 551.1649,found 551.1667.
实施例13：2-甲基-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)-3-((6-吗啉代咪唑并[1,2-b]哒嗪-3-基)乙炔基)苯甲酰胺(命名为XS3-68)的制备
Figure PCTCN2021117495-appb-000037
合成方法如实施例6。
1H NMR(400MHz,Chloroform-d)δ8.22(s,1H),7.98(s,1H),7.82(s,1H),7.77(s,1H),7.70(d,J＝9.8Hz,1H),7.62(dd,J＝7.7,1.4Hz,1H),7.45–7.40(m,2H),7.26(d,J＝7.7Hz,1H),6.86(d,J＝9.9Hz,1H),3.88–3.84(m,4H),3.59(s,2H),3.57–3.53(m,4H),2.71(s,3H),2.52(s,8H),2.32(s,3H).LC-MS(ESI)m/z 618.3[M+H] +.
实施例14：(S)-3-((6-(3-羟基吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基-N-(3-(三氟甲基)苯基)苯甲酰胺(命名为XS3-35)的制备
Figure PCTCN2021117495-appb-000038
合成方法如实施例6。
1HNMR(400MHz,Chloroform-d)δ8.16(s,1H),8.05(s,1H),7.91(d,J＝8.1Hz,1H),7.74(s,1H),7.65–7.57(m,2H),7.54(t,J＝7.9Hz,1H),7.46(d,J＝7.8Hz,1H),7.41(d,J＝7.9Hz,1H),7.24(t,J＝7.6Hz,1H),6.58(d,J＝8.8Hz,1H),5.03(d,J＝3.7Hz,1H),4.42(s,1H),3.62–3.50(m,3H),3.40(d,J＝11.3Hz,1H),2.67(s,3H),2.10–1.98(m,1H),1.92(d,J＝12.9Hz,1H).
.LC-MS(ESI)m/z 504.2[M-H] -.
实施例15:(S)-N-(3-氯-5-(三氟甲基)苯基)-3-((6-(3-羟基吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基苯甲酰胺(命名为XS3-58)的制备
Figure PCTCN2021117495-appb-000039
合成方法如实施例6。
1H NMR(400MHz,Chloroform-d)δ8.27(s,1H),8.08(s,1H),7.86(s,1H),7.72(s,1H),7.64–7.59(m,2H),7.44(d,J＝1.8Hz,1H),7.39(dd,J＝7.7,1.4Hz,1H),7.25(t,J＝7.7Hz,1H),6.60(d,J＝9.6Hz,1H),4.66(s,1H),3.70–3.54(m,5H),2.71(s,3H),2.16(dd,J＝7.9,3.9Hz,2H).LC-MS(ESI)m/z 540.0[M+H] +.
实施例16:(S)-3-((6-(3-羟基吡咯烷-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)苯甲酰胺(命名为XS3-36)的制备
Figure PCTCN2021117495-appb-000040
合成方法如实施例6。
1H NMR(400MHz,Chloroform-d)δ8.18(s,1H),8.02(s,1H),7.79(s,1H),7.72(s,1H),7.63–7.58(m,2H),7.41(d,J＝5.1Hz,2H),7.25(t,J＝7.7Hz,1H),6.58(d,J＝9.7Hz,1H),4.64(dd,J＝4.3,2.2Hz,1H),3.68–3.56(m,7H),2.74(s,3H),2.51(s,8H),2.31(s,3H),2.17–2.09(m,2H).LC-MS(ESI)m/z 618.3[M+H] +.
实施例17:3-((6-(4-(二甲基氨基)哌啶-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基-N-(3-(三氟甲基)苯基)苯甲酰胺(命名为XS3-57)的制备
Figure PCTCN2021117495-appb-000041
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.78(s,1H),8.27(d,J＝2.3Hz,1H),7.95(d,J＝2.6Hz,1H),7.93(d,J＝3.2Hz,1H),7.90(s,1H),7.68(dd,J＝7.7,1.4Hz,1H),7.61(t,J＝8.1Hz,1H), 7.55(dd,J＝7.7,1.4Hz,1H),7.48(d,J＝7.8Hz,1H),7.42(t,J＝7.7Hz,1H),7.34(d,J＝10.0Hz,1H),4.30(d,J＝13.4Hz,2H),2.97(t,J＝12.0Hz,2H),2.65(s,3H),2.34(s,6H),1.90(d,J＝12.1Hz,2H),1.57–1.41(m,3H).LC-MS(ESI)m/z 547.2[M+H] +.
实施例18:N-(3-氯-5-(三氟甲基)苯基)-3-((6-(4-(二甲基氨基)哌啶-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基苯甲酰胺(命名为XS3-56)的制备
Figure PCTCN2021117495-appb-000042
合成方法如实施例6。
1H NMR(400MHz,Chloroform-d)δ8.30(s,1H),8.09(d,J＝2.3Hz,1H),7.86(s,1H),7.74(s,1H),7.66–7.60(m,2H),7.44(s,1H),7.40(dd,J＝7.7,1.4Hz,1H),7.28–7.23(m,1H),6.90(d,J＝9.9Hz,1H),4.26(d,J＝12.9Hz,2H),2.98(t,J＝12.8Hz,2H),2.72(s,3H),2.41(t,J＝11.2Hz,1H),2.33(s,6H),2.01–1.93(m,2H),1.66–1.54(m,2H).LC-MS(ESI)m/z 579.3[M-H] -.
实施例19:3-((6-(4-(二甲基氨基)哌啶-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基-N-(3-((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)苯甲酰胺(命名为XS3-67)的制备
Figure PCTCN2021117495-appb-000043
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.75(s,1H),8.15(s,1H),7.92(d,J＝9.8Hz,2H),7.89(s,1H),7.67(d,J＝6.4Hz,1H),7.54(d,J＝6.9Hz,1H),7.40(t,J＝7.7Hz,1H),7.37(s,1H),7.32(d,J＝10.0Hz,1H),4.26(d,J＝13.0Hz,2H),3.54(s,2H),2.96(t,J＝12.1Hz,2H),2.64(s,3H),2.45–2.29(m,8H),2.18(s,6H),2.16(s,3H),2.00(q,J＝7.5Hz,1H),1.83(d,J＝11.5Hz,2H),1.44(q,J＝10.5,9.3Hz,2H).LC-MS(ESI)m/z 658.3[M+H] +.
实施例20:N-(3-氯-5-(三氟甲基)苯基)-2-甲基-3-((6-(4-甲基哌嗪-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)苯甲酰胺(命名为XS3-51)的制备
Figure PCTCN2021117495-appb-000044
合成方法如实施例6。
1H NMR(400MHz,Chloroform-d)δ8.08(s,2H),7.86(s,1H),7.83(d,J＝3.4Hz,1H),7.78–7.72(m,1H),7.66(d,J＝7.6Hz,1H),7.46(d,J＝7.7Hz,1H),7.43(s,1H),7.32(d,J＝7.7Hz,1H),6.89(d,J＝9.9Hz,1H),3.80(s,4H),3.13(s,3H),2.74(s,3H),2.53(d,J＝21.6Hz,4H).LC-MS(ESI)m/z 553.2[M+H] +.
实施例21:(R)-N-(3-氯-5-(三氟甲基)苯基)-3-((6-(3,4-二甲基哌嗪-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基苯甲酰胺(命名为XS3-52)的制备
Figure PCTCN2021117495-appb-000045
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.93(s,1H),8.13(s,2H),8.06(s,1H),7.97(s,1H),7.71(d,J＝7.2Hz,1H),7.62(s,1H),7.58(d,J＝7.3Hz,1H),7.44(t,J＝7.6Hz,1H),7.39(d,J＝9.5Hz,1H),3.13—3.06(m,4H),2.91(s,2H),2.75(m,1H),2.65(s,3H),2.46(s,3H),1.24(s,3H).LC-MS(ESI)m/z 567.2[M+H] +.
实施例22：N-(3-氯-5-(三氟甲基)苯基)-3-((6-(4-羟基哌啶-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基苯甲酰胺(命名为XS3-55)的制备
Figure PCTCN2021117495-appb-000046
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.93(s,1H),8.14(d,J＝1.8Hz,2H),7.94–7.88(m,2H),7.69(dd,J＝7.7,1.4Hz,1H),7.61(s,1H),7.56(dd,J＝7.7,1.4Hz,1H),7.42(t,J＝7.7Hz,1H),7.32(d,J＝10.0Hz,1H),4.71(d,J＝4.2Hz,1H),4.00–3.93(m,2H),3.74(m,1H),3.25(t,J＝13.1Hz,2H),2.64(s,3H),1.82(d,J＝12.8Hz,2H),1.49– 1.40(m,2H).LC-MS(ESI)m/z 552.1[M-H] -.
实施例23：3-((6-(4-乙酰基哌嗪-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-N-(3-氯-5-(三氟甲基)苯基)-2-甲基苯甲酰胺(命名为XS3-54)的制备
Figure PCTCN2021117495-appb-000047
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.93(s,1H),8.14(d,J＝1.7Hz,2H),7.98(d,J＝9.9Hz,1H),7.93(s,1H),7.71(dd,J＝7.7,1.3Hz,1H),7.61(d,J＝2.0Hz,1H),7.57(dd,J＝7.7,1.4Hz,1H),7.43(t,J＝7.7Hz,1H),7.34(d,J＝10.0Hz,1H),3.66–3.53(m,8H),2.65(s,3H),2.04(s,3H).LC-MS(ESI)m/z581.5[M+H]+.
实施例24：N-(3-氯-5-(三氟甲基)苯基)-2-甲基-3-((6-((2-吗啉代乙基)氨基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)苯甲酰胺(命名为XS3-53)的制备
Figure PCTCN2021117495-appb-000048
合成方法如实施例6。
1H NMR(400MHz,Chloroform-d)δ8.28(s,1H),8.08(s,1H),7.87(s,1H),7.66(d,J＝7.7Hz,2H),7.47(d,J＝7.5Hz,1H),7.44(s,1H),7.34(d,J＝7.9Hz,1H),7.31(s,1H),6.73(s,2H),4.01(s,4H),3.78(s,2H),3.19(s,2H),3.05(s,4H),2.71(s,3H).LC-MS(ESI)m/z583.2[M+H]+
实施例25：3-((6-(4-羟基哌啶-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基-N-(3-(((4-甲基哌嗪-1-基)甲基)-5-(三氟甲基)苯基)苯甲酰胺(命名为XS3-81)的制备
Figure PCTCN2021117495-appb-000049
合成方法如实施例6。
1H NMR(400MHz,Chloroform-d)δ8.36(s,1H),8.01(s,1H),7.80(s,1H),7.73(s,1H),7.62(d,J＝9.9Hz,1H),7.59(dd,J＝7.8,1.4Hz,1H),7.43–7.38(m,2H),7.24(t,J＝7.7Hz,1H),6.88(d,J＝9.9Hz,1H),4.0–3.91(m,3H),3.59(s,2H),3.28(t,J＝13.1Hz,2H),2.70(s,3H),2.51(s,8H),2.31(s,3H),1.99–1.95(m,2H),1.69–1.61(m,2H).LC-MS(ESI)m/z632.3[M+H] +.
实施例26：N-(3-氯-5-(三氟甲基)苯基)-2-甲基-3-((6-(4-吗啉哌啶-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)苯甲酰胺(命名为XS3-130)的制备
Figure PCTCN2021117495-appb-000050
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.93(s,1H),8.13(s,2H),7.92(d,J＝9.8Hz,2H),7.69(d,J＝7.3Hz,1H),7.61(s,1H),7.56(d,J＝7.4Hz,1H),7.42(t,J＝7.7Hz,1H),7.33(d,J＝9.8Hz,1H),4.26(d,J＝13.0Hz,2H),3.54(s,4H),2.97(t,J＝12.3Hz,2H),2.64(s,3H),2.45(s,5H),1.86(d,J＝12.8Hz,2H),1.45(d,J＝12.2Hz,2H).HRMS(ESI)for C 32H 30ClF 3N 6O 2[M+H] +:calcd 623.2144,found 623.2126.
实施例27：N-(3-氯-5-(三氟甲基)苯基)-2-甲基-3-((6-(4-(氧杂环丁基-3-基)哌嗪-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)苯甲酰胺(命名为XS3-138)的制备
Figure PCTCN2021117495-appb-000051
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.92(s,1H),8.13(s,2H),7.98–7.87(m,2H),7.69(d,J＝8.2Hz,1H),7.61(s,1H),7.56(d,J＝6.9Hz,1H),7.42(t,J＝7.7Hz,1H),7.34(d,J＝9.9Hz,1H),4.55(t,J＝6.5Hz,2H),4.47(t,J＝6.1Hz,2H),3.60(t,J＝5.1Hz,4H),3.45(m,1H),2.63(s,3H),2.40(t,J＝5.0Hz,4H).HRMS(ESI)for C 30H 26ClF 3N 6O 2[M+H] +:calcd 595.1831,found  595.1811.
实施例28：N-(3-氯-5-(三氟甲基)苯基)-3-((6-((2-(二甲氨基)乙基)(甲基)氨基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基苯甲酰胺(命名为XS3-134)的制备
Figure PCTCN2021117495-appb-000052
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.92(s,1H),8.13(d,J＝1.8Hz,2H),7.90–7.82(m,2H),7.68(dd,J＝7.7,1.4Hz,1H),7.60(d,J＝1.8Hz,1H),7.55(dd,J＝7.8,1.3Hz,1H),7.41(t,J＝7.7Hz,1H),7.14(d,J＝10.0Hz,1H),3.64(t,J＝6.7Hz,2H),3.09(s,3H),2.63(s,3H),2.45(t,J＝6.7Hz,2H),2.16(s,6H).HRMS(ESI)for C 28H 26ClF 3N 6O[M+H] +:calcd 555.1881,found 555.1862.
实施例29：N-(3-氯-5-(三氟甲基)苯基)-3-((6-((2-甲氧基乙基)氨基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基苯甲酰胺(命名为XS3-135)的制备
Figure PCTCN2021117495-appb-000053
合成方法如实施例6。
1H NMR(600MHz,DMSO-d 6)δ10.93(s,1H),8.14–8.09(m,2H),7.81–7.73(m,2H),7.67(dd,J＝7.7,1.3Hz,1H),7.59(d,J＝1.9Hz,1H),7.54(dd,J＝7.7,1.3Hz,1H),7.41(t,J＝7.7Hz,1H),7.27(t,J＝5.5Hz,1H),6.82(d,J＝9.6Hz,1H),3.54(t,J＝5.5Hz,2H),3.47–3.45(m,2H),3.26(s,3H),2.63(s,3H).HRMS(ESI)for C 26H 21ClF 3N 5O 2[M+H] +:calcd 528.1409,found 528.1394.
实施例30：N-(3-氯-5-(三氟甲基)苯基)-3-((6-((4-羟基丁基)氨基)咪唑[1,2-b]哒嗪-3-基)乙炔基)-2-甲基苯甲酰胺(命名为XS3-139)的制备
Figure PCTCN2021117495-appb-000054
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.92(s,1H),8.12(s,2H),7.76(d,J＝9.6Hz,2H),7.68(dd,J＝7.7,1.4Hz,1H),7.61(s,1H),7.55(dd,J＝7.7,1.4Hz,1H),7.41(t,J＝7.7Hz,1H),7.16(t,J＝5.3Hz,1H),6.77(d,J＝8.9Hz,1H),4.38(t,J＝5.1Hz,1H),3.43–3.37(m,2H),3.30–3.25(m,2H),2.65(s,3H),1.70–1.59(m,2H),1.53–1.46(m,2H).HRMS(ESI)for C 27H 23ClF 3N 5O 2[M+H] +:calcd 542.1565,found 542.1552.
实施例31：3-((6-(4-氨基哌啶-1-基)咪唑[1,2-b]哒嗪-3-基)乙炔基)-N-(3-氯-5-(三氟甲基)苯基)-2-甲基苯甲酰胺(命名为XS3-131)的制备
Figure PCTCN2021117495-appb-000055
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.96(s,1H),8.15(s,2H),7.96(d,J＝9.9Hz,1H),7.92(s,1H),7.70(dd,J＝7.8,1.3Hz,1H),7.61(d,J＝2.3Hz,1H),7.57(dd,J＝7.7,1.3Hz,1H),7.43(t,J＝7.7Hz,1H),7.34(d,J＝10.0Hz,1H),4.23(d,J＝13.4Hz,2H),3.17(s,2H),3.12–3.02(m,2H),2.65(s,3H),2.63(m,1H),1.89(d,J＝11.2Hz,2H),1.48(q,J＝11.7,10.8Hz,2H).HRMS(ESI)for C 28H 24ClF 3N 6O[M+H] +:calcd 553.1725,found 553.1708.
实施例32：(R)-3-((6-(3-氨基哌啶-1-基)咪唑[1,2-b]哒嗪-3-基)乙炔基)-N-(3-氯-5-(三氟甲基)苯基)-2-甲基苯甲酰胺(命名为XS3-137)的制备
Figure PCTCN2021117495-appb-000056
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.93(s,1H),8.13(s,2H),7.92–7.85(m,2H),7.69(d,J＝7.6Hz,1H),7.60(s,1H),7.55(d,J＝7.6Hz,1H),7.42(t,J＝7.7Hz,1H),7.28(d,J＝10.0Hz,1H),4.04(dd,J＝10.6,6.5Hz,2H),2.98(m,1H),2.78–2.69(m,2H),2.65(s,3H),1.86(m,1H),1.74(m,1H),1.61–1.43(m,2H).HRMS(ESI)for C 28H 24ClF 3N 6O[M+H] +:calcd 553.1725,found 553.1706.
实施例33：(S)-3-((6-(3-氨基哌啶-1-基)咪唑[1,2-b]哒嗪-3-基)乙炔基)-N-(3-氯-5-(三氟甲基)苯基)-2-甲基苯甲酰胺(命名为XS3-136)的制备
Figure PCTCN2021117495-appb-000057
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.93(s,1H),8.13(s,2H),7.95–7.84(m,2H),7.69(d,J＝7.6Hz,1H),7.60(s,1H),7.55(d,J＝7.6Hz,1H),7.42(t,J＝7.7Hz,1H),7.28(d,J＝10.0Hz,1H),4.04(dd,J＝11.5,5.9Hz,2H),3.04–2.93(m,2H),2.80–2.70(m,2H),2.65(s,3H),1.86(d,J＝12.0Hz,1H),1.74(m,1H),1.53(q,J＝11.8Hz,1H).HRMS(ESI)for C 28H 24ClF 3N 6O[M+H] +:calcd 553.1725,found 553.1703.
实施例34：N-(3-氯-5-(三氟甲基)苯基)-3-(6-(4-羟基-4-甲基哌啶-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基苯甲酰胺(命名为XS3-153)的制备
Figure PCTCN2021117495-appb-000058
合成方法如实施例6。
1H NMR(400MHz,DMSO-d 6)δ10.93(s,1H),8.13(t,J＝2.1Hz,2H),7.90(d,J＝10.2Hz,2H),7.69(dd,J＝7.7,1.4Hz,1H),7.61(d,J＝1.8Hz,1H),7.56(dd,J＝7.7,1.4Hz,1H),7.42(t,J＝7.7Hz,1H),7.32(d,J＝10.0Hz,1H),4.39(s,1H),3.92–3.83(m,2H),3.44–3.37(m,2H),2.64(s,3H),1.55(t,J＝5.6Hz,4H),1.15(s,3H).HRMS(ESI)for C 29H 25ClF 3N 5O 2[M+H] +:calcd 568.1722,found 568.1699.
实施例35：2-甲基-N-(3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基)-3-((6-吗啉代咪唑并[1,2-b]吡啶并-3-基乙炔基)苯甲酰胺(命名为XS3-91)的制备
Figure PCTCN2021117495-appb-000059
步骤1：4-甲基-1-(3-硝基-5-(三氟甲基)苯基)-1H-咪唑(化合物3)的制备
Figure PCTCN2021117495-appb-000060
将化合物1 1g(4.5mmol)，化合物2 800mg(9.5mmol)溶于20mL二甲基亚砜(DMSO)中，然后加入850mg(7mmol)碳酸钾。120℃加热搅拌，过夜反应。旋干反应体系，柱层析得到黄白色固体430mg(收率36％)。
1H NMR(400MHz,Chloroform-d)δ8.46(q,J＝1.9Hz,2H),8.02–7.97(m,2H),7.17(s,1H),2.36(d,J＝1.0Hz,3H).LC-MS(ESI)m/z 272.1[M+H] +.
步骤2：3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯胺(化合物4)的制备
Figure PCTCN2021117495-appb-000061
将化合物3 430mg(1.59mmol)溶于乙醇：水为7:3的混合溶剂中，加入盐酸溶液使得反应体系称弱酸性，然后加入444mg(7.93mmol)铁粉。70℃加热搅拌2小时。硅藻土过滤，旋干反应体系，粗产品直接用于下一步反应。
步骤3：3-乙炔基-2-甲基-N-(3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基)苯甲酰 胺(化合物6)的制备
Figure PCTCN2021117495-appb-000062
将化合物4 270mg(1.12mmol)，化合物5 215mg(1.3mmol)溶于15mL的N,N-二甲基甲酰胺(DMF)中，然后加入638mg(1.68mmol)2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)，216mg(1.68mmol)N,N-二异丙基乙胺(DIPEA)。80℃加热搅拌，过夜反应。旋干反应体系，加水，用乙酸乙酯萃取，水洗，无水硫酸钠干燥，旋干溶剂，柱层析得到黄色油状物220mg(收率51％)。
1H NMR(400MHz,Chloroform-d)δ9.41(s,1H),8.22(s,1H),7.91(s,1H),7.73(s,1H),7.55(d,J＝7.6Hz,1H),7.43(d,J＝7.2Hz,1H),7.34(s,1H),7.19(t,J＝7.7Hz,1H),7.09(s,1H),3.34(s,1H),2.58(s,3H),2.25(s,3H).LC-MS(ESI)m/z 384.1[M+H] +.
步骤4：2-甲基-N-(3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基)-3-((6-吗啉代咪唑并[1,2-b]吡啶并-3-基乙炔基)苯甲酰胺(命名为XS3-91)的制备
Figure PCTCN2021117495-appb-000063
将化合物6 150mg(0.39mmol)和化合物7 130mg(0.47mmol)溶于10mL无水N,N-二甲基甲酰胺(DMF)中，然后加入碘化亚铜6mg(0.03mmol)，三二亚苄基丙酮二钯17mg(0.019mmol)，三叔丁基磷8mg(0.039mmol)，碳酸钾107mg(0.78mmol)，置换氩气，封闭反应体系。80℃加热搅拌，过夜反应。用硅藻土过滤，旋干滤液，柱层析得到黄白色固体40mg(收率18％)。
1H NMR(400MHz,DMSO-d 6)δ10.92(s,1H),8.20(d,J＝1.6Hz,2H),8.10(s,1H),7.98(d,J＝9.9Hz,1H),7.93(s,1H),7.76(s,1H),7.72–7.69(m,1H),7.57(d,J＝7.4Hz,1H),7.48(s,1H),7.44(d,J＝7.7Hz,1H),7.32(d,J＝10.0Hz,1H),3.77–3.72(m,4H),3.54(t,J＝4.9Hz,4H),2.65(s,3H),2.19(d,J＝1.0Hz,3H).LC-MS(ESI)m/z 586.6[M+H] +.
实施例36：3-((6-(4-羟基哌啶-1-基)咪唑并[1,2-b]哒嗪-3-基)乙炔基)-2-甲基-N-(3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基)苯甲酰胺(命名为XS3-87)的制备
Figure PCTCN2021117495-appb-000064
合成方法如实施例35。
1H NMR(400MHz,Chloroform-d)δ8.25(s,1H),7.97(s,1H),7.88(s,1H),7.83(s,1H),7.75–7.70(m,2H),7.68(d,J＝7.7Hz,1H),7.47(d,J＝7.5Hz,1H),7.42(s,1H),7.33(t,J＝7.7Hz,1H),7.13(s,1H),6.93(d,J＝9.9Hz,1H),4.05–3.97(m,3H),3.37–3.29(m,2H),2.78(s,3H),2.33(d,J＝1.0Hz,3H),2.03(d,J＝9.6Hz,2H),1.69(d,J＝9.5Hz,3H).LC-MS(ESI)m/z600.0[M+H] +.
实施例37 化合物对TRKs激酶的IC 50测试
激酶活性检测：应用Z′-LYTE TM技术(采用荧光进行检测、酶偶联形式，以磷酸化和非磷酸化多肽对蛋白水解切割的敏感性差异为基础)，采用荧光共振能量转移(FRET)原理，使用Z′-LYTE TM FRET肽类底物，二级反应检测化合物对TRKs(TRK1,TRK2,TRK3)激酶(美国生命技术公司,PV3144,PV3616,PV3617)的抑制活性。
酶促反应：384孔板中，加入5μL酶-底物体系[50mM4-羟乙基哌嗪乙磺酸(HEPES)pH 7.5,0.01％BRIJ-35,10mM氯化镁(MgCl 2),1mM乙二醇双(2-氨基乙基醚)四乙酸(EGTA),2μM Tyr 01肽底物，利用echo520超微量液体移液系统转入5nL化合物(浓度梯度)，室温震荡10-20min后，利用echo520超微量液体移液系统分别转入200nL,12.5nL,25nLATP(终浓度分别为400uM,25uM,50uM)，震荡混匀后离心，30℃避光反应1.5h。
检测反应：每孔加入2.5μL反应液(Development Solution)(1:128稀释)37℃避光孵育1h，然后加入5μL终止液(Stop Reagent)。
读板：多标记微孔板检测仪(Perkin Elmer EnVision Multimode Plate Reader)检测荧光信号(激发光波长为400nm，发射光波长为460nm、535nm)。
计算：通过全活性孔和对照信号孔计算出每个孔的抑制率，数据分析方法如下：
磷酸化比率＝1–{(发射比×F100％–C100％)/[C 0％–C 100％+发射比×(F100％–F0％)]}×100；
抑制率＝100×(1–化合物磷酸化比率/阴性对照磷酸化比率)。
IC 50值采用医学绘图软件(GraphPad Prism5.0)软件计算求得。
激酶活性测试结果如表1所示。
表1 化合物激酶活性测试结果(IC 50:nM)
化合物编号 TRKA TRKB TRKC
XS116 ** ** **
XS2-161 *** **** ***
XS2-106 *** ****  
XS2-109 *** **** ***
XS2-112 *** *** ***
XS3-23 ** ** **
XS3-61 ** ** **
XS4-80 **   **
XS4-81 **   **
XS4-72 ** ** **
XS4-76 ** ** **
XS4-77 ** ** **
XS3-68 * * *
XS3-35 * ** *
XS3-58 ** ** **
XS3-36 ** ** *
XS3-57 * * *
XS3-56 ** ** **
XS3-67 * ** *
XS3-51 ** ** *
XS3-52 ** ** **
XS3-55 * ** **
XS3-54 * ** *
XS3-53 * ** *
XS3-81 * * *
XS3-130 ** ** *
XS3-138 ** * *
XS3-134 ** ** **
XS3-135 ** ** **
XS3-139 ** ** **
XS3-131 ** ** **
XS3-137 ** ** **
XS3-136 ** ** **
XS3-153 ** ** **
XS3-91 * * *
XS3-87 * * *
IC 50:<10nM＝*；10-100nM＝**；100-1000nM＝***；>1uM＝****。
从表1数据可以看出，本发明的炔苯基苯酰胺类化合物对TRKs激酶有很强的抑制活性。
实施例38：基于Ba/F3-TRKs稳定株的细胞增殖抑制活性研究
本实验使用的BaF3细胞(小鼠前B细胞)购自日本细胞库，BaF3-CD74-NTRK1、BaF3-ETV6-NTRK2、BaF3-ETV6-NTRK3单克隆稳定株均由本实验室构建，并通过阳性药活性、蛋白表达及基因测序等实验鉴定完全正确。
稳定株构建的简要步骤如下：构建携带CD74-NTRK1、ETV6-NTRK2、ETV6-NTRK3等基因的pCDNA3.1(+)质粒载体；使用
Figure PCTCN2021117495-appb-000065
Cell Line
Figure PCTCN2021117495-appb-000066
Kit V试剂盒将质粒电转入Ba/F3细胞；电转48小时后，加入终浓度为1000μg/ml的遗传霉素(G418)筛选两周并撤去白介素3(IL3)继续筛选，获得多克隆稳定株；然后通过极限稀释法挑选单克隆；进而使用阳性药、蛋白免疫印迹(Western Blot，WB)、基因测序对稳定株进行鉴定；鉴定完全正确的单克隆即可用于抑制剂的细胞增殖抑制活性研究。
细胞增殖抑制活性研究：将对数生长期的细胞按8000-12000个/孔接种到96孔板，次日加入不同浓度的抑制剂(0-10μM)，继续培养72小时；然后每孔加入10μL Cell Counting Kit-8细胞计数试剂(CCK-8试剂)，继续孵育1-3小时；接着用超级酶标仪测定其在450nm及650nm的吸光值。使用医学绘图软件(GraphPad Prism 8.0.0)计算半数抑制浓度(IC 50)。
测试结果如表2所示。
表2 化合物细胞活性测试结果(IC 50:nM)
Figure PCTCN2021117495-appb-000067
Figure PCTCN2021117495-appb-000068
Figure PCTCN2021117495-appb-000069
IC 50:<10nM＝*；10-100nM＝**；100-1000nM＝***；>1uM＝****。
从表2数据可以看出，本发明的炔苯基苯酰胺类化合物对Ba/F3-TRKs稳定株的细胞增殖有很强的抑制活性。
实施例39：基于Ba/F3-TRKs稳定株的耐药细胞增殖抑制活性研究
本实验使用的BaF3细胞(小鼠前B细胞)购自日本细胞库，BaF3-CD74-NTRK1-G667C、BaF3-CD74-NTRK1-F589L、BaF3-CD74-NTRK1-G595R、BaF3-CD74-NTRK1-G667A、BaF3-CD74-NTRK1-V573M、BaF3-ETV6-NTRK2-G639R、BaF3-ETV6-NTRK2-G709C、BaF3-ETV6-NTRK2-V617M、BaF3-ETV6-NTRK2-F633L、BaF3-ETV6-NTRK3-G696C、BaF3-ETV6-NTRK3-G696A、BaF3-ETV6-NTRK3-G623R、BaF3-ETV6-NTRK3-G623E、BaF3-ETV6-NTRK3-F617L、BaF3-ETV6-NTRK3-V601M单克隆稳定株均由本实验室构建，并通过阳性药活性、蛋白表达及基因测序等实验鉴定完全正确。
稳定株构建的简要步骤如下：构建携带BaF3-CD74-NTRK1-G667C、BaF3-CD74-NTRK1-F589L、BaF3-CD74-NTRK1-G595R、BaF3-CD74-NTRK1-G667A、BaF3-CD74-NTRK1-V573M、BaF3-ETV6-NTRK2-G639R、BaF3-ETV6-NTRK2-G709C、BaF3-ETV6-NTRK2-V617M、BaF3-ETV6-NTRK2-F633L、BaF3-ETV6-NTRK3-G696C、BaF3-ETV6-NTRK3-G696A、BaF3-ETV6-NTRK3-G623R、BaF3-ETV6-NTRK3-G623E、BaF3-ETV6-NTRK3-F617L、BaF3-ETV6-NTRK3-V601M等基因的pCDNA3.1(+)质粒载体；使用
Figure PCTCN2021117495-appb-000070
Cell Line
Figure PCTCN2021117495-appb-000071
KitV试剂盒将质粒电转入Ba/F3细胞；电转48小时后，加入终浓度为1000μg/ml的遗传霉素(G418)筛选两周并撤去白介素3(IL3)继续筛选，获得多克隆稳定株；然后通过极限稀释法挑选单克隆；进而使用阳性药、蛋白免疫印迹(Western Blot，WB)、基因测序对稳定株进行鉴定；鉴定完全正确的单克隆即可用于抑制剂的细胞增殖抑制活性研究。
细胞增殖抑制活性研究：将对数生长期的细胞按8000-12000个/孔接种到96孔板，次日加入不同浓度的抑制剂(0-10μM)，继续培养72小时；然后每孔加入10μL Cell Counting Kit-8细胞计数试剂(CCK-8)试剂，继续孵育1-3小时；接着用超级酶标仪测定其在450nm及650nm的吸光值。使用医学绘图软件(GraphPad Prism 8.0.0)计算半数抑制浓度(IC 50)。
测试结果如表3所示。
表3 化合物耐药细胞活性测试结果(IC 50:nM)
化合物编号 XS3-55 XS3-68 XS3-81 XS3-87
BaF3-CD74-NTRK1-G667C * * * *
BaF3-CD74-NTRK1-G667A * * * *
BaF3-CD74-NTRK1-G595R **** *** *** ***
BaF3-CD74-NTRK1-F589L *** *** *** **
BaF3-CD74-NTRK1-V573M ** ** * *
BaF3-ETV6-NTRK2-G639R *** ** ** **
BaF3-ETV6-NTRK2-F633L *** *** *** **
BaF3-ETV6-NTRK2-V617M * * * *
BaF3-ETV6-NTRK2-G709C * * ** *
BaF3-ETV6-NTRK3-G696C * * * *
BaF3-ETV6-NTRK3-G696A * * * *
BaF3-ETV6-NTRK3-G623R *** ** ** **
BaF3-ETV6-NTRK3-G623E * * * *
BaF3-ETV6-NTRK3-F617L ** ** ** *
BaF3-ETV6-NTRK3-V601M * * * *
IC 50:<10nM＝*；10-100nM＝**；100-1000nM＝***；>1uM＝****。
从表3数据可以看出，本发明的炔苯基苯酰胺类化合物对Ba/F3-TRKs稳定株的耐药细胞增殖有很强的抑制活性。
实施例40 化合物XS3-55激酶选择性的IC 50测试
激酶活性检测：应用Z′-LYTE TM技术(采用荧光进行检测、酶偶联形式，以磷酸化和非磷酸化多肽对蛋白水解切割的敏感性差异为基础)，采用荧光共振能量转移(FRET)原理，使用Z′-LYTE TM FRET肽类底物，二级反应检测化合物XS3-55及对照分子XS4-128和Ponatinib(帕纳替尼)对Bcr-Abl，SRC，RET,,PDGFRA,PDGFRB,VEGFR2和Kit激酶的抑制活性。
其中，化合XS4-128的结构式如下：
Figure PCTCN2021117495-appb-000072
其制备方法如下：
Figure PCTCN2021117495-appb-000073
步骤1：甲基4-甲基-3-((三甲基甲硅烷基)乙炔基)苯甲酸酯(化合物2)的制备
Figure PCTCN2021117495-appb-000074
100mL三颈瓶中，加入化合物1 1g(3.6mmol)，碘化亚铜69mg(0.36mmol)，二(三苯基膦)二氯化钯127mg(0.18mmol)，无水乙腈50mL，N,N-二异丙基乙胺934mg(7.2mmol)，置换氩气，封闭反应体系，然后用注射器注入三甲基硅乙炔1.06g(10.8mmol)，60℃搅拌6小时。用硅藻土过滤反应液，旋干溶剂得到黑色混合物，直接用于下一步反应。
步骤2：甲基3-乙炔基-4-甲基苯甲酸甲酯(化合物3)的制备
Figure PCTCN2021117495-appb-000075
将上一步粗产品用甲醇溶解，加入约2mL的1mol/L四丁基氟化铵的四氢呋喃溶液，常温搅拌2小时。旋干反应体系，柱层析得到黄棕色油状物470mg(两步总产率75％)。
1H NMR(400MHz,DMSO-d 6)δ8.06(d,J＝1.5Hz,1H),7.76(dd,J＝7.5,1.5Hz,1H),7.25(dd,J＝7.5,1.0Hz,1H),4.25(s,1H),3.86(s,3H),2.39(s,3H).LC-MS(ESI)m/z 175.5[M+H] +.
步骤3：3-乙炔基-4-甲基苯甲酸(化合物4)的制备
Figure PCTCN2021117495-appb-000076
将化合物3 400mg(2.29mmol)溶于体积比为10：1：5的四氢呋喃、甲醇和水的混合溶剂中，然后加入氢氧化锂的水合物482mg(11.4mmol)，60℃搅拌1小时。过滤，旋干反应体系，然后加入4M盐酸溶液直至体系呈酸性，此时有白色固体析出，过滤收集白色固体，干燥，得到白色固体350mg(产率96％)。
1H NMR(400MHz,DMSO-d 6)δ13.02(s,1H),7.93(d,J＝1.8Hz,1H),7.85(dd,J＝7.9,1.9Hz,1H),7.43(d,J＝8.0Hz,1H),4.48(s,1H),2.45(s,3H).LC-MS(ESI)m/z 160.9[M+H] +.
步骤4：N-(3-氯-5-(三氟甲基)苯基)-3-乙炔基-4-甲基苯甲酰胺(化合物6)的制备
Figure PCTCN2021117495-appb-000077
将化合物4 300mg(1.9mmol)，化合物5 305mg(1.6mmol)溶于20mL的N,N-二甲基甲酰胺(DMF)中，加入2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯(HATU)912mg(2.4mmol)，N,N-二异丙基乙胺413mg(3.2mmol)。70℃加热搅拌2小时。旋干反应体系，加水，用乙酸乙酯萃取，水洗，无水硫酸钠干燥，旋干溶剂，柱层析得到黄色油状物340mg(产率63％)。
1H NMR(400MHz,DMSO-d 6)δ10.88(s,1H),8.11(d,J＝1.8Hz,2H),7.64–7.57(m,2H),7.54(dd,J＝7.7,1.4Hz,1H),7.36(t,J＝7.7Hz,1H),4.51(s,1H),2.47(s,3H).MS(ESI)m/z335.8[M-H] -.
步骤5：N-(3-氯-5-(三氟甲基)苯基)-3-((6-(4-羟基哌啶-1-基)咪唑[1,2-B]哒嗪-3-基)乙炔基)-4-甲基苯甲酰胺(XS4-128)的制备
Figure PCTCN2021117495-appb-000078
将化合物6 70mg(0.2mmol)和化合物7 83mg(1.2mmol)溶于10mL无水N,N-二甲基甲酰胺(DMF)中，然后加入碘化亚铜8mg(0.016mmol)，二(三苯基膦)二氯化钯19mg(0.01mmol)，N,N-二异丙基乙胺145mg(0.4mmol)，置换氩气，封闭反应体系。80℃加热搅拌，过夜反应。用硅藻土过滤，旋干滤液，柱层析得到黄白色固体80mg(产率73％)。
1H NMR(400MHz,DMSO-d 6)δ10.66(s,1H),8.25(s,2H),8.16(d,J＝9.2Hz,2H),7.96(s,1H),7.90(dd,J＝8.0,1.9Hz,1H),7.55(s,1H),7.52(d,J＝8.1Hz,1H),7.34(s,1H),4.75(d,J＝ 4.2Hz,1H),3.98(d,J＝14.5Hz,2H),3.80–3.71(m,1H),3.26(t,J＝11.5Hz,2H),2.61(s,3H),1.89–1.78(m,2H),1.54–1.40(m,2H).HRMS(ESI)for C 28H 23ClF 3N 5O 2[M+H] +:calcd 554.1565,found 554.1562.
酶促反应：384孔板中，加入5μL酶-底物体系(50mM 4-羟乙基哌嗪乙磺酸(HEPES)pH7.5,0.01％BRIJ-35,10mM氯化镁(MgCl 2),1mM乙二醇双(2-氨基乙基醚)四乙酸(EGTA),2μM Tyr 01肽底物)，利用echo520超微量液体移液系统转入5nL化合物(浓度梯度)，室温震荡10-20min后，利用echo520超微量液体移液系统分别转入200nL,12.5nL,25nLATP(终浓度分别为400uM,25uM,50uM)，震荡混匀后离心，30℃避光反应1.5h。
检测反应：每孔加入2.5μL反应液(Development Solution)(1:128稀释)37℃避光孵育1h，然后加入5μL终止液(Stop Reagent)。
读板：多标记微孔板检测仪(Perkin Elmer EnVision Multimode Plate Reader)检测荧光信号(激发光波长为400nm，发射光波长为460nm、535nm)。
计算：通过全活性孔和对照信号孔计算出每个孔的抑制率，数据分析方法如下：
磷酸化比率＝1–{(发射比×F100％–C100％)/[C 0％–C 100％+发射比×(F100％–F0％)]}×100；
抑制率＝100×(1–化合物磷酸化比率/阴性对照磷酸化比率)。
IC 50值采用医学绘图软件(GraphPad Prism5.0)软件计算求得。
激酶活性测试结果如表4所示。
表4 化合物激酶选择性活性测试结果(IC 50:nM)
激酶 XS3-55 XS4-128 Ponatinib
Bcr-Abl >10000 128.8 3.9
SRC 526.3 20.3 2.0
RET >10000 10.7 3.3
VEGFR2 832.7 18.9 3.3
Kit 1669 93.5 25.1
PDGFRA 5887 19.9 3.9
PDGFRB >10000 118.9 18.0
从表4数据可以看出，本发明的炔苯基苯酰胺类代表性化合物XS3-55对TRKA,TRKB,TRKC以外的多种代表性酪氨酸激酶的抑制活性较弱，其具有较好的激酶选择性，其激酶选择性远远好于化合物XS4-128和Ponatinib，因此，本发明的炔苯基苯酰胺类化合物的选择性好，毒副作用低。
实施例41：药代动力学评价
以SD大鼠进行药代动力学和口服生物利用度测试，根据药物溶解性，分别口服，静脉注射单次给药，在不同的时间点(0，0.5，1，2，4，6，8，24小时)分别采集动物血样，加肝素抗凝，离心取上清。HPLC-MS方法分析血样，使用DAS2.1进行数据分析，检测半衰期(T1/2)、最高血药浓度(Cmax)、达峰时间(Tmax)、药时曲线下面积(AUC)、生物利用度(BA)等药代动力学数据。化合物XS3-55和化合物9o(European Journal ofMedicinal Chemistry 179(2019)470-482.)的药代动力学数据结果如表5所示：
Figure PCTCN2021117495-appb-000079
表5
Figure PCTCN2021117495-appb-000080
化合物XS3-55对TRKs激酶有很强的抑制活性，并且对Ba/F3-TRKs稳定株的野生型及耐药型细胞增殖有很强的抑制活性。且化合物XS3-55具有很好的口服吸收性质，在大鼠口服10mg/kg的剂量下，化合物XS3-55的半衰期为15.19小时，最高血药浓度高达44066.54ng/mL，药时曲线下面积高达878346.33h*ng/mL，药代动力学性质显著高于对照化合物9o。
实施例42：化合物XS3-55体内肿瘤活性
通过口服给药，在Ba/F3-CD74-TRKA G667C同种异体移植小鼠模型中评估了化合物XS3-55的体内抗肿瘤药效。将培养的BaF3-CD74-TRKA G667C细胞收集、离心，用生理盐水洗涤两次后调整密度至1×10 7个/mL后置于冰上，尽快皮下注射于CB17-SCID雌鼠右腋(购自北京维通利华，6-8周龄)，每只注射200μL。造模9天后，瘤体积生长至约200mm 3时随机分组并开始给药，其中对照组8只小鼠，化合物XS3-55四个剂量组(50、25、12.5、6.25mg/kg)每组6只小鼠。给药方式如下：按给药剂量称取适量化合物XS3-55粉末溶于2％二甲基亚砜(DMSO)+20％氢化蓖麻油+8％无水乙醇+70％生理盐水的混合溶剂中，得到浅黄色至黄色透明液体，口服给药，每天给药一次；对照组口服给予同等体积的混合溶剂。每两天记录一次体重及瘤体积。
结果如图1所示：化合物XS3-55每天给药一次，持续两周，以剂量依赖性方式抑制携带CD74TRKA G667C突变同种异体移植小鼠模型的生长。以最低剂量6.25mg/kg治疗2天后观察到肿瘤大小显着减小。治疗12天后，化合物XS3-55在6.25mg/kg/天、12.5mg/kg/天、25mg/kg/天和50mg/kg/天的剂量下表现出优异的体内抗肿瘤药效，TGI分别为50.9％、76.3％、89.2和91.6％，而对照组小鼠在第14天时死亡。同时，体内研究显示四种不同剂量的化合物XS3-55都对小鼠体重没有明显的不利影响(图1中的A图)，这表明化合物XS3-55具有良好的安全性。
以上所述实施例的各技术特征可以进行任意的组合，为使描述简洁，未对上述实施例中的各个技术特征所有可能的组合都进行描述，然而，只要这些技术特征的组合不存在矛盾，都应当认为是本说明书记载的范围。
以上所述实施例仅表达了本发明的几种实施方式，其描述较为具体和详细，但并不能因此而理解为对发明专利范围的限制。应当指出的是，对于本领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干变形和改进，这些都属于本发明的保护范围。因此，本发明专利的保护范围应以所附权利要求为准。

Claims (19)

  1. 具有式(I)结构的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子；
    Figure PCTCN2021117495-appb-100001
    其中，R 1任选自：C 1～C 20烷基；
    R 2任选自：H、卤素、C 1～C 20烷基、C 1～C 20烷氧基或卤素取代的C 1～C 20烷基；
    R 3任选自：H、氟取代的C 1～C 4烷基、取代或未取代的含1-3个N环原子的5-6元杂环基；
    R 4任选自：H、卤素、硝基、取代或未取代的C 1～C 20烷基、取代或未取代的C 1～C 20烷氧基、取代或未取代的含1-3个N环原子的5-10元杂环基、取代或未取代的含1-3个N环原子的5-10元杂芳基；
    R 5为-NR 6R 7；
    其中，R 6、R 7分别独立地选自：-(CH 2) mNR 8R 9、-(CH 2) nCR 10R 11R 12、-(CH 2) pOR 12，或者R 6、R 7与它们所连接的氮原子一起形成被取代或未被取代的含有杂原子的单环、稠环、螺环或桥环；
    R 8、R 9分别独立地选自：H、C 1～C 20烷基；或者R 8、R 9与它们所连接的氮原子一起形成被取代或未被取代的含有1-3个杂原子的单环、稠环、螺环或桥环；
    R 10、R 11与它们所连接的碳原子一起形成被取代或未被取代的含有1-3个杂原子的单环、稠环、螺环或桥环；
    R 12选自：H、C 1～C 20烷基；
    m、n、p分别独立地选自：0-10的整数。
  2. 根据权利要求1所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 4任选自：H、卤素、硝基、C 1～C 8烷基、卤素取代的C 1～C 8烷基、C 1～C 8烷氧基、卤素取代的C 1～C 8烷氧基、-(CH 2) xNR 17R 18、被1-5个R 19取代或未被取代的含有1-3个N环原子的5-6元杂环基、被1-5个R 19取代或未被取代的含有1-3个N环原子的5-6元杂芳基；x为1-5的整数；
    R 17、R 18与它们所连接的氮原子一起形成被1-5个R 19取代或未被取代的吗啉基、吡咯烷基、哌啶基或哌嗪基；
    各R 19分别独立地选自：C 1-C 5烷基。
  3. 根据权利要求2所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 4任选自：H、卤素、硝基、C 1～C 4烷基、卤素取代的C 1～C 4烷基、C 1～C 4烷氧基、卤素取代的C 1～C 4烷氧基、-(CH 2) xNR 17R 18、被1-3个R 19取代或未被取代的咪唑基；x为1、2或3；
    R 17、R 18与它们所连接的氮原子一起形成被1-3个R 19取代或未被取代的哌嗪基；
    各R 19分别独立地选自：C 1-C 5烷基。
  4. 根据权利要求3所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 4任选自：H、卤素、硝基、甲基、乙基、丙基、甲氧基、乙氧基、丙氧基、三氟甲基、三氟乙基、
    Figure PCTCN2021117495-appb-100002
    各R 19分别独立地选自：甲基、乙基、丙基。
  5. 根据权利要求1所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 6、R 7分别独立地选自：-(CH 2) mNR 8R 9、-(CH 2) nCR 10R 11R 12、-(CH 2) pOR 12，或者R 6、R 7与它们所连接的氮原子一起形成被1-5个R 13取代或未被取代的含有1-3个杂原子的3-15元单环、稠环、螺环或桥环，杂原子选自：O、N、S；
    R 8、R 9分别独立地选自：H、C 1～C 5烷基；或者R 8、R 9与它们所连接的氮原子一起形成被1-5个R 13取代或未被取代的含有1-3个杂原子的3-10元单环、稠环、螺环或桥环，杂原子选自：O、N；
    R 10、R 11与它们所连接的碳原子一起形成被1-5个R 13取代或未被取代的含有1-3个杂原子的3-10元单环、稠环、螺环或桥环，杂原子选自：O、N；
    R 12选自：H、C 1-C 5烷基；
    各R 13分别独立地选自：H、C 1-C 5烷基、C 1-C 5烷酰基、羟基、羟基取代的C 1-C 5烷基、氨基取代的C 1-C 5烷基、氨基取代的C 1-C 5烷氧基、C 3-C 7环烷基取代的C 1-C 3烷基、-NR 15R 16、被1-5个R 14取代或未被取代的含有1-3个杂原子的3-10元单环、稠环、螺环或桥环，杂原子选自：O、N；
    R 14、R 15、R 16分别独立地选自：H、C 1-C 5烷基；
    m、n、p分别独立地选自：0-5的整数。
  6. 根据权利要求5所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 6、R 7分别独立地选自：-(CH 2) mNR 8R 9、-(CH 2) pOR 12，或者R 6、R 7与它们所连接的氮原子一起形成被1-3个R 13取代或未被取代的吗啉基、吡咯烷基、哌啶基或者哌嗪基；
    R 8、R 9分别独立地选自：H、C 1～C 5烷基，或者R 8、R 9与它们所连接的氮原子一起形成被1-5个R 13取代或未被取代的吗啉基、吡咯烷基、哌啶基或哌嗪基；
    R 12选自：H、C 1-C 5烷基；
    各R 13分别独立地选自：H、C 1-C 5烷基、C 1-C 5烷酰基、羟基、-NR 15R 16、被1-2个R 14取代或未被取代的氧杂环丁基、被1-4个R 14取代或未被取代的吗啉基；
    R 14、R 15、R 16分别独立地选自：H、C 1-C 3烷基；
    m、p分别独立地选自：1、2、3、4或5。
  7. 根据权利要求5所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，R 5选自以下任意一种基团：
    Figure PCTCN2021117495-appb-100003
    Figure PCTCN2021117495-appb-100004
  8. 根据权利要求1所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，R 4为卤素；R 5为-NR 6R 7；
    R 6、R 7分别独立地选自：-(CH 2) mNR 8R 9、-(CH 2) pOR 12，或者R 6、R 7与它们所连接的氮原子一起形成被1-3个R 13取代或未被取代的吗啉基、吡咯烷基、哌啶基或者哌嗪基；
    R 8、R 9分别独立地选自：H、C 1-C 3烷基，或者R 8、R 9与它们所连接的氮原子一起形成被1-2个R 13取代或未被取代的吗啉基、吡咯烷基、哌啶基或哌嗪基；
    R 12选自：H、C 1-C 3烷基；
    各R 13分别独立地选自：H、C 1-C 3烷基、乙酰基、羟基、-NR 15R 16、氧杂环丁基、吗啉基；
    R 15、R 16分别独立地选自：H、C 1-C 3烷基；
    m、p分别独立地选自：2、3或4。
  9. 根据权利要求8所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，R 4为Cl，
    R 5选自：
    Figure PCTCN2021117495-appb-100005
    Figure PCTCN2021117495-appb-100006
  10. 根据权利要求1所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 4选自：H、卤素、甲基、甲氧基、三氟甲基、硝基、
    Figure PCTCN2021117495-appb-100007
    R 5为
    Figure PCTCN2021117495-appb-100008
    或者，R 4选自：H、
    Figure PCTCN2021117495-appb-100009
    R 5选自：
    Figure PCTCN2021117495-appb-100010
    或者，
    R 4为
    Figure PCTCN2021117495-appb-100011
    R 5选自：
    Figure PCTCN2021117495-appb-100012
  11. 根据权利要求1～10任一项所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 1任选自：C 1～C 4烷基；和/或，
    R 2任选自：H、卤素、C 1～C 4烷基、卤素取代的C 1～C 4烷基、C 1～C 4烷氧基。
  12. 根据权利要求11所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 1任选自：甲基、乙基、异丙基、叔丁基；和/或，
    R 2任选自：氢、氟、甲基、乙基、异丙基、叔丁基、二氟甲基、二氟乙基、三氟甲基或三氟乙基。
  13. 根据权利要求1～10任一项所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，
    R 3选自：H、二氟甲基、二氟乙基、三氟甲基或三氟乙基。
  14. 根据权利要求1～10任一项所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子，其特征在于，具有式(II)所示结构：
    Figure PCTCN2021117495-appb-100013
  15. 根据权利要求1所述的炔苯基苯酰胺类化合物或其药学上可接受的盐或其立体异构体，其特征在于，所述炔苯基苯酰胺类化合物选自以下化合物：
    Figure PCTCN2021117495-appb-100014
    Figure PCTCN2021117495-appb-100015
    Figure PCTCN2021117495-appb-100016
    Figure PCTCN2021117495-appb-100017
  16. 权利要求1～15一项所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子在制备TRK抑制剂中的应用。
  17. 权利要求1～18一项所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子在制备预防和/或治疗由TRK酪氨酸激酶介导的疾病的药物中的应用。
  18. 权利要求17述的应用，其特征在于，所述由TRK酪氨酸激酶介导的疾病为肿瘤，优选为非小细胞肺癌、乳腺癌、结肠癌、前列腺癌、甲状腺癌、恶性黑色素瘤、神经母细胞瘤和乳腺样分泌癌。
  19. 一种预防和/或治疗肿瘤的药用组合物，其特征在于，包括活性成分和药学上可接受的辅料，所述活性成分包括权利要求1～15任一项所述的炔苯基苯酰胺类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子。
PCT/CN2021/117495 2021-04-13 2021-09-09 炔苯基苯酰胺类化合物及其应用 WO2022217821A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020237038624A KR20230170938A (ko) 2021-04-13 2021-09-09 알키닐페닐벤즈아미드계 화합물 및 이의 응용
JP2023564002A JP2024514015A (ja) 2021-04-13 2021-09-09 アルキニルフェニルベンズアミド化合物およびその使用
AU2021440841A AU2021440841A1 (en) 2021-04-13 2021-09-09 Alkynylphenylbenzamide compound and use thereof
BR112023021215A BR112023021215A2 (pt) 2021-04-13 2021-09-09 Compostos de alquinilfenilbenzamida, usos dos mesmos e composição farmacêutica compreendendo os referidos compostos
EP21936693.7A EP4324833A1 (en) 2021-04-13 2021-09-09 Alkynylphenylbenzamide compound and use thereof
US17/948,236 US11834454B2 (en) 2021-04-13 2022-09-20 Alkynylphenylbenzamide compounds and applications thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110395086 2021-04-13
CN202110395086.2 2021-04-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/948,236 Continuation US11834454B2 (en) 2021-04-13 2022-09-20 Alkynylphenylbenzamide compounds and applications thereof

Publications (1)

Publication Number Publication Date
WO2022217821A1 true WO2022217821A1 (zh) 2022-10-20

Family

ID=78958920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/117495 WO2022217821A1 (zh) 2021-04-13 2021-09-09 炔苯基苯酰胺类化合物及其应用

Country Status (8)

Country Link
US (1) US11834454B2 (zh)
EP (1) EP4324833A1 (zh)
JP (1) JP2024514015A (zh)
KR (1) KR20230170938A (zh)
CN (1) CN113831344B (zh)
AU (1) AU2021440841A1 (zh)
BR (1) BR112023021215A2 (zh)
WO (1) WO2022217821A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117510504A (zh) * 2022-08-05 2024-02-06 深圳市新樾生物科技有限公司 蛋白激酶降解剂、药物及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013101281A1 (en) * 2011-04-07 2013-07-04 Ariad Pharmaceuticals, Inc. Methods and compositions for treating parkinson's disease
WO2014019338A1 (en) * 2012-07-30 2014-02-06 Astar Biotech Llc Protein kinase inhibitors
WO2015108490A2 (en) * 2014-01-17 2015-07-23 Agency For Science, Technology And Research Heteroaryl alkyne derivatives and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2495016T3 (da) * 2005-12-23 2019-12-16 Ariad Pharma Inc Bicykliske heteroarylforbindelser
WO2015085972A1 (en) * 2013-12-09 2015-06-18 Zentiva, K.S. NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
US10925868B2 (en) * 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013101281A1 (en) * 2011-04-07 2013-07-04 Ariad Pharmaceuticals, Inc. Methods and compositions for treating parkinson's disease
WO2014019338A1 (en) * 2012-07-30 2014-02-06 Astar Biotech Llc Protein kinase inhibitors
WO2015108490A2 (en) * 2014-01-17 2015-07-23 Agency For Science, Technology And Research Heteroaryl alkyne derivatives and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERG ET AL.: "Pharmaceutical Salts", J. PHARM. SCI, vol. 66, 1977, pages 1 - 19

Also Published As

Publication number Publication date
US20230046126A1 (en) 2023-02-16
JP2024514015A (ja) 2024-03-27
CN113831344A (zh) 2021-12-24
CN113831344B (zh) 2022-09-16
US11834454B2 (en) 2023-12-05
BR112023021215A2 (pt) 2023-12-19
EP4324833A1 (en) 2024-02-21
AU2021440841A1 (en) 2023-10-19
KR20230170938A (ko) 2023-12-19

Similar Documents

Publication Publication Date Title
WO2021073439A1 (zh) 用于抑制shp2活性的吡嗪衍生物
US9962382B2 (en) Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
WO2019042470A1 (zh) CD47/SIRPα的阻断剂及其应用
WO2018149382A1 (zh) 含邻氨基杂芳环炔基的化合物及其制备方法和用途
WO2020259683A1 (zh) 2，4-二取代嘧啶衍生物及其制备方法和用途
CN104470934B (zh) 蛋白激酶抑制剂
WO2018018986A1 (zh) 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN109153669B (zh) 苯甲酰胺类化合物的新晶型
CN103596568A (zh) 治疗帕金森病的方法以及组合物
CN103582478A (zh) 治疗神经退行性疾病的方法和组合物
CA3032795A1 (en) Imidazopyridinamine phenyl derivative and use thereof
WO2016124160A1 (zh) 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用
CN110563697A (zh) 2-吡啶甲酰胺类化合物的制备及应用
WO2022217821A1 (zh) 炔苯基苯酰胺类化合物及其应用
WO2017144025A1 (zh) 作为EGFR抑制剂的嘧啶并[4,5-d][1,3]噁嗪-2-酮衍生物及其应用
WO2024099168A1 (zh) 一种2,4,5-三取代嘧啶类化合物及其制备方法和用途
WO2021121146A1 (zh) 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用
CN107793363B (zh) 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
CN110467616B (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
CN107235906B (zh) 一组吡唑酰胺类衍生物及其应用
CN111574503A (zh) 一种嘧啶双芳香环衍生物表皮生长因子抑制剂及其制备方法与用途
CN109384788A (zh) 嘌呤系列衍生物及其制备方法和用途
CN115322158A (zh) 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
WO2021249558A1 (zh) 作为rsk抑制剂的蝶啶酮衍生物及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21936693

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2021440841

Country of ref document: AU

Ref document number: 2021440841

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2301006465

Country of ref document: TH

WWE Wipo information: entry into national phase

Ref document number: 2023564002

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2021440841

Country of ref document: AU

Date of ref document: 20210909

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023021215

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20237038624

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020237038624

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2021936693

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021936693

Country of ref document: EP

Effective date: 20231113

ENP Entry into the national phase

Ref document number: 112023021215

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20231011